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ABSTRACT 
Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) characterized 
by highly aggressive phenotype, unfavorable prognosis and lack of specific therapy. At 
the molecular level TNBC resembles basal-like subtype of BC, characterized by high 
prevalence of missense point mutations in the TP53 gene, one of the most frequent 
genetic events in human cancers. Mutant-p53 proteins on one hand lose wild-type tumor 
suppressive functions but, on the other, acquire oncogenic properties (“gain-of-
function”, GOF) that actively contribute to tumorigenesis.  
Studies in aggressive breast cancer-derived cell lines underscored a central role of mut-
p53 in cell-polarity disruption and acquisition of highly aggressive phenotype. 
Increasing knowledge about the mechanism that regulates the establishment and 
maintenance of cell polarity, have reveled its important contributions in preventing 
acquisition of tumorigenic features, but it is still challenging to understand how cancer 
genes and pathway influence epithelial architecture. 
Despite the increasing knowledge of mut-p53 functions, little is known about 
microRNAs associated with mut-p53. 
Here we investigated whether mut-p53 GOFs exerted in TNBC could be in part 
mediated by miRNAs whose expression is promoted mut-p53. In MDA-MB-231 
(TNBC cells harboring endogenous mut-p53) we performed a screening of miRNAs 
previously described to be overexpressed in BC and other solid tumors. Among 
miRNAs positively regulated by mut-p53 we identified miR-30d. 
 Results of further experiments suggest that mut-p53/miR-30d axis plays an important 
role in inducing epithelial cell polarity disruption and causes aggressive cancer 
phenotypes, such as cellular migration and invasion.  
We also identified and validated targets of the mutp53/miR-30d axis that could be 
involved in mediating their biological effects. In particular we identified DLG5 as a key 
gene whose suppression by mut-p53/miR-30d seems to be correlated with epithelial cell 
polarity disruption and causes cancer aggressiveness. 
We propose that understanding pathways affected by miR-30d will provide new 
insights that can be exploited in discovery of novel therapeutic targets and diagnostic 
markers in TNBC. 
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INTRODUCTION 
Breast Cancer 
Cancer is one of the leading causes of death in humans. While the affected organs are 
different in male and female, according to the 2012 IARC (International Agency for 
Research on Cancer) statistics (Figure 1), Breast Cancer is the most commonly 
diagnosed cancer, and the leading cause of cancer death among women worldwide. 
 
Figure 1. Estimated age-standardised incidence and mortality rates in women. (form IA2012 IARC statistics)   
Death rates from breast cancer have been declining since about 1989, with largest 
decreases in women younger than 50 years of age. These decreases are believed to be 
the result of earlier detection through screening and increased awareness, as well as 
improved treatment. Most patients die due to distant metastases, frequently 
unresponsive to therapies. Despite significant advances in diagnostics and treating 
several unresolved clinical and scientific issues have to be resolved. 
Breast cancer classification 
Breast cancer is a heterogeneous disease at clinical, morphological and molecular point 
of view. The development of high throughput technologies has allowed the 
classification of breast cancer not only looking traditional parameters (such us tumor 
size, lymph node involvement, grade, and age) but also they permitted to joint a 
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characterization and subtype classification lied to gene expression (Perou et al., 2000; 
Sorlie et al., 2001).  
Gene expression profiling of breast cancer sample allowed identification of five major 
molecular subtypes: luminal A, luminal B, HER2 positive, basal-like and claudin-low; 
this led the clinicians to better diagnosis and patients treatments. 
Luminal A is the most common BC (50-60% of all cases), defined by 
immunohistochemistry as estrogen receptor (ER) positive, and HER2 negative, 
characterized by low proliferation rate and have a good prognosis. 
Luminal B (10-20% of all BC tumors) differs from luminal A subtype by a high 
proliferation rate, estimated by Ki67 proliferation-related antigen staining. They have a 
worse prognosis than Luminal A but they respond better to chemotherapy. 
Her2-positive subtype represents 10-15% of breast cancer and highly expresses HER2 
gene or genes associated with the HER2 pathway. Commonly they have a high 
histological grade, and are characterized by poor prognosis. 
10-20% of BC correspond to basal-like subtype - they express typical myoepithelial 
genes (cytokeratins CK5 and CK17, P-cadherin, caveolin 1 and 2, nestin, CD44 and 
EGFR) and have a worst prognosis, with high mitotic index, high metastatic relapse in 
visceral organs (lung, central nervous system, lymph nodes). Despite the basal-like and 
triple negative (TN) are often regarded as synonymous, TN represents not all, but the 
most common basal-like breast cancer - they are negative for ER, PGR and HER2 
expression. Treatment for this subtype is very difficult, as well as identification of new 
therapeutics targets. The most frequent alterations are p53 mutations and impaired 
activity of BRCA1 (Bertucci et al., 2012). 
Another subtype, identified in 2007, is the Claudin-low subtype, whose predominant 
feature is low expression of tight junctions and intracellular adhesion genes (claudin-3, -
4, -7 and E-cadherin) and overexpression of immuno-response related genes, due to 
high immune-system infiltration (Prat et al., 2010). This subset is rare (12-14%), has a 
poor prognosis, is linked to mesenchymal differentiation and cancer stem cells (CSC) 
phenotype. 
A poorly characterized and infrequent subtype of breast cancer is named Normal Breast, 
it occurs only in 5-10% of cases end it express genes typical of adipose tissue, it lacks 
ER, PGR and HER2 receptor, but it is also missing of CK5 and EGFR basal marker. 
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Usually this kind of BC displays an intermediate prognosis and also response to 
chemotherapy. 
The breast cancer classification based on distinct molecular breast cancer subtypes 
could permit to stratify breast cancer patients and better personalize treatments. 
Nevertheless it is still needed to investigate signaling pathways involved in tumor 
formation and progression, in order to better define treatment and prognosis for the 
subtypes. 
Deregulated pathways in cancer progression 
Hallmarks of cancer. Cancer is a multistep process in which normal cells progressively 
acquires a series of characteristics the enable them to become tumorigenic. These new 
features could be resumed by six biological capabilities that support tumor growth and 
metastasis. They were described first in 2000 by Hanahan and Weinberg (Hanahan and 
Weinberg, 2000) and named hallmarks of cancer. They include six essential steps that 
allow cells to proliferate, survive and disseminate (sustained proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis and activating invasion and metastasis). In contrast to normal 
cells, cancer cells achieve proliferative independence, they became able to elude the 
homeostatic control of cell cycle and start to proliferate - mostly due to an acquired  
growth factor signaling capability, by increasing their bioavailability, enhancing the 
signaling downstream to their receptors, or circumventing negative feedback that in 
normal condition control growth-stimulatory signals. Thus cancer cells, in addition to 
increased proliferation, are unresponsive to suppression of growth factors, event often 
due as a result of mutations in tumor suppressors genes like p53. 
Moreover, unlike normal cells, tumor cell are also able to escape programmed cell 
death. Apoptosis works like a barrier to cancer development; it is triggered in response 
of various endogenous stresses (like DNA damage) in the intrinsic program, or by 
extracellular death-inducing signal (extrinsic program). Tumor cells adopt a variety of 
strategies to limit the apoptosis triggering; again the most common way is the loss of 
damage sensor TP53, but also by increasing expression of antiapoptotic regulators, and 
by downregulating proapoptotic factors. 
In addition, regarding the proliferative capability, normal cells are able to pass through a 
limited number of divisions, and then they irreversibly entry in a non-proliferative state 
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called senescence, this process is controlled by the shortening of telomeres, 
chromosomes end made by repetitive tandem hexanucleotide that protect from erosion 
of genetic material, and act as a clock in limiting replicative potential. To escape this 
control cancer cells increase telomerases expression, thus acquiring replicative 
immortality. 
Like normal cells, tumors cell require nutrients and oxygen, they supply these needs by 
inducing “angiogenic switch”, causing the formation of new vessels. 
Finally tumor cells start to invade first the surrounding tissue and then distant site 
forming metastasis. The invasion and metastasis is a multistep process, often termed the 
invasion-metastasis cascade (Valastyan and Weinberg, 2011). It began with local 
invasion trough extracellular matrix and stromal cell layer, followed by intravasation of 
cancer cells into blood and lymphatic vessels, transit of cancer cells through 
hematogenous systems in which they have to survive. Then the metastatic cells are able 
to escape from the lumina of such vessels into the parenchyma of distant tissues 
(extravasation), surviving in a foreign microenvironment in order to form 
micrometastases, and finally reinitiate the growth generating macroscopic metastasis, 
this last step being termed ‘‘colonization’’(Valastyan and Weinberg, 2011). 
In addition to this hallmark of cancer, a new process that can facilitate tumor growth has 
been described and named “enabling capabilities”. 
Obviously, to be able to support cell growth and proliferation, cancer cells reprogram 
their cellular energy metabolism, for example to accomplish these needs cells become 
more dependent to glucose metabolism, and react by upregulating glucose transport 
(Jones and Thompson, 2009). 
Lastly, during tumor growth and metastasis a relevant factor is the crosstalk between 
cancer cells and the surrounding microenvironment including also the immune system. 
Paradoxically, in opposition to classical role of immune system in preventing cancer, 
another enabling hallmark is represented by inflammation that supplies bioactive 
molecules to the tumor microenvironment, such us growth factors, proangiogenic 
factors, extracellular matrix-modifying enzymes that facilitate angiogenesis, invasion, 
and metastasis, facilitating cancer programs (Grivennikov et al., 2010).  
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Epithelial Cell polarity as a barrier against cancer 
Carcinomas are malignant cancers arising from epithelial tissue, and according to 
American Cancer Society they constitute ~80% of all cancers.  
Alterations in epithelial polarity are hallmark of cancer and contribute to carcinomas 
development and progression, indicating high metastatic potential. Whereas primary 
tumor can be cured by surgical resection and adjuvant therapy, metastatic disease that 
causes >90% of mortality attributed to cancer, is often incurable because of its systemic 
nature and resistance of metastatic cells to therapeutic agents (Wan et al., 2013). 
Epithelial Cell Polarity overview 
Epithelium is formed by cells arranged in sheets that function as a barrier between 
compartments or between the inside and the outside of an organism. One of its main 
roles is to transport molecules from one to the other side of the barrier. Polarization 
consists of creating series of specialized cell junctions with neighboring cells that are 
essential for the correct organization and function (St Johnston and Ahringer, 2010). 
In epithelia this spatial arrangement and differentiated protein composition of 
membrane domains facilitate cellular processes as diverse as differentiation, localized 
membrane growth, activation of the immune response, directional cell migration, and 
directional transport of molecules across cell layers (Simons and Mlodzik, 2008). 
Polarity touches essentially every aspect of cell and developmental biology. Correct 
establishment and maintenance of cell polarity are needed for normal cell physiology 
and tissue homeostasis. Cell polarization allows cells to sense and to elicit the proper 
spatiotemporal responses to signals that arise from neighboring cells and the 
surrounding microenvironment, and then to transduce an intracellular signal in order to 
generate an asymmetry, creating different cell surface domains with distinct chemical 
and physical properties.  
Cell polarity is relevant to single cell systems, such as yeast, as well as multicellular 
organisms, in every mechanism; e.g. during development and morphogenesis, polarity 
along cells in a tissue (in particular apico-basal polarity in epithelial cells), and also in 
physio-pathological such us cell migration during wound healing, or cancer 
transformation (Wodarz and Nathke, 2007). 
Despite the structural and functional diversity, establishment and maintenance of cell 
polarity share the same core mechanisms. When cells sense a cell-surface landmark or 
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spatial cue (e.g cytokinesis in budding and fission yeast, and cell–cell adhesion in 
epithelial cells from worms, flies and mammals) they initiate to define a point on the 
cell surface to which they orient (mother–daughter axis in yeast, and the apicobasal 
axis), inducing the assembly and orientation of actin and microtubule cytoskeleton 
(Yamashita et al., 2010). 
The Epithelium is the first tissue that emerge during ontogenesis, and epithelial cells 
have fundamental role in embryo morphogenesis and organ development (Bryant and 
Mostov, 2008). Polarization involves the concerted, timed and integrated actions of 
numerous genes (Edwards, 2005).  
 
Figure 2. Intercellular Junctions and Polarity Factors in Epithelial Cells 
A-B Representation of two typical epithelial cells in vertebrates and Drosophila, showing the cell structure and the 
junction. In vertebrates (A) the apical tight junction, which functions as a paracellular diffusion barrier, forms as a 
result of homophilic interactions between Junctional Adhesion Molecules (JAM), Occludins, and Claudins. Adherens 
junctions, which localize on the lateral side beneath the tight junctions, consist of Cadherins and Nectins. (B) In 
Drosophila epithelial cells, the arrangement of junctions is reversed, with apical adherens junctions and more basal 
septate junctions, which form the paracellular diffusion barrier. Epithelial cells in the fly have a polarized spectrin 
cytoskeleton. 
 C-D In vertebrates and Drosophila, complexes of polarity proteins establish and maintain these local domains inside 
the epithelial cell. These two diagrams show the locations of the major polarity complexes and important interactions 
between them in mammalian (C) and Drosophila (D) epithelial cells. (adapted from(Rodriguez-Boulan and Macara, 
2014) 
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The establishment and orientation of the apical-basal polarity axis is a key event during 
the acquisition of the epithelial phenotype, and it is established very early during 
embryogenesis.  
Epitelial cell polarity has been extensively studied in Drosophila, where the apical-basal 
axis is organized differently from vertebrates, in particular the arrangement of lateral 
junction is reverse respect mammalian ones, with adherens junction localized more 
apically to the septate junction (Figure 2) (Rodriguez-Boulan and Macara, 2014). 
Although there are differences in some details, surprising parallels have been observed 
between epithelial cell polarity establishment in vertebrates and invertebrates (Figure 2 
C-D). In all the systems it starts with the formation of cell-cell contact thanks to E-
cadherin, followed by actin cytoskeleton reorganization. 
In Drosophila the polarization begin in the oocyte that becomes polarized before 
fertilization with complementary domains of polarity proteins at the cortex. 
In Drosophila polarity is established and maintained by the interplay of three key 
complex: The PAR-3 complex, contains Bazooka, PAR-6, and atypical protein kinase C 
(aPKC), localizes along the anterior and lateral cortex, whereas PAR-1 and lethal giant 
larvae (Lgl) localize at the posterior. These polarity proteins regulate the organization of 
the microtubule cytoskeleton so that microtubules are nucleated from the anterior and 
lateral cortex but not from the posterior. This creates an anterior to posterior gradient of 
microtubule that then directs the transport of embryonic determinant mRNAs to the 
anterior and the posterior region. 
In Drosophila melanogaster, the separation of the apical domain from the most apical 
region of the basolateral domain presents many similarities to the polarization of 
mammalian cells. Moreover, Mammalian homologues of lgl, dlg and scrib are 
functionally conserved and can rescue the mutant phenotypes of the respective 
Drosophila genes in vivo. (Wodarz and Nathke, 2007) 
Conversly, mammalian embryogenesis starts by zygotic cell division that generate a 
blastula epithelium thought cavitation, compaction, and fluid transport after the 8-16 
cell stage (Ziomek and Johnson, 1980). 
In Mammalian embryos, at this stage called morula, cell blastomeres start to 
differentiate, and polarity Par3, Par6 and aPKC begin to localize asymmetrically at tight 
junction levels (Figure 3A). (Plusa et al., 2005). Par family proteins were first identified 
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in C. elegans roundworms by a genetic screen for mutant lethal genes in early partition 
development (Kemphues et al., 1988). In mammalian embryos Par-related proteins 
regulate spindle orientation, thus some cells divide equally to produce identical progeny 
and others divide transversely to produce two different outer and inner cell layers, so 
starting the differentiation. 
In adults, epithelial tissues have an asymmetrical organization, in order to maintain 
tissue structures and perform a number of specialized functions in a body. 
At cellular level this is achieved thanks to junctions, positioned along the later side of 
epithelial cells, creating four distinct plasma-membrane domains, which have a different 
composition of protein and lipids: an apical domain, tight junctions (TJ),  adherens 
junctions (AJ), and a basolateral domain (Figure 3B) , while in Drosophila the 
arrangement of lateral junction is reverse respect mammalian ones, with adherens 
junction localized more apically to the septate junction. 
The apical domain usually is formed by a border of microvilli, constituted of actin and 
spectrin filaments, linked to plasma membrane through the ERM protein family (Ezrin, 
Moesin, and Radixin) (St Johnston and Ahringer, 2010). 
The TJs constitute a boundary between the apical and lateral domain, and they are 
formed by homophilic interaction of adhesion molecules, such as Occludin, Junctional 
Adhesion Molecules (JAMs), and the Claudins. The role of TJs is to create a fence 
between the apical and lateral domains, that prevents diffusion of membrane proteins. 
Adherens junctions are localized below the TJ and they mediate the hemophilic cell-cell 
interaction. AJs are composed of cadherins β-catenin and α-catenin (and their 
cytoplasmic adaptor proteins) (Nelson, 2008). Nectins also localize to these junctions 
and connect the junctional complex to the actin cytoskeleton through the adaptor protein 
Afadin/AF-6 (Takai et al., 2008). 
The basal side of cells directly interacts with the extracellular matrix or basement 
membrane though integrins and distroglycans. 
This strictly organized structures is acquired thanks to the Epithelial cell polarity 
program (EPP) that integrates two different machineries, polarized trafficking and the a 
domain identity program (Tanos and Rodriguez-Boulan, 2008). 
The polarized trafficking machinery is composed of secretory organelles (the 
endoplasmic reticulum and Golgi complex) and endosomal compartments. The 
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polarized trafficking machinery adapts cytoskeleton and a secretory or recycling-
endocytic system to accomplish polarized sorting and delivery of protein and lipids to 
the different domains of plasma membrane (Tanos and Rodriguez-Boulan, 2008). 
The domain identity program consists of a fast identity program due to different 
distribution of phosphatidylinositol lipids along the membrane. The interplay between 
the lipid phosphatase and tensin homolog (PTEN), through its product 
phosphatidylinositol 4,5-bisphosphate (PIP2), and the phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3kinase), through the phosphatidylinositol (3,4,5)-
trisphosphate (PIP3), enable fast domain-identity establishment (Royer and Lu, 2011).  
These two phospholipids play a key role in polarization initiation, they have a distinct 
localization, PIP2 concentrates at the apical membrane, while PIP3 is localized to the 
basolateral membrane (Gassama-Diagne et al., 2006). PIP2 starts polarization by 
recruiting Annexin 2, which in turns recruits active Cdc42-GTP, where it binds and 
activates the PAR-6/aPKC complex triggering the domain identity program (Martin-
Belmonte and Perez-Moreno, 2011). 
Structural and functional polarity is obtained by the concerted action of three well-
conserved polarity complexes, namely PAR, Crumbs (CRB) and SCRIB. The interplay 
of these complexes control the assembly of tight junctions and adherens junctions, 
controlling the formation and maintenance of the apical and basolateral domains 
(Martin-Belmonte and Mostov, 2008). 
The PAR polarity complex, comprising PAR3, PAR6 and aPKC promotes the 
establishment of the apical-basal membrane border. The role of the small GTPase 
molecule CDC42 is essential for this complex.  CdC42 physically interacts with Par6; 
this interaction was discovered in C. elegans embryos, and seems to be conserved from 
worms to mammals. In human three PAR6 homologous have been identified 
(PARD6A-B-G) and two PAR3 homologous (PAR3α-β) (Noda et al., 2001). 
PAR3α was shown to be involved in tight junction establishment in epithelial cells. 
Interaction of mammalian aPKC with PAR3/PAR6 appears to be an important 
prerequisite for establishment of cell polarity (Helfrich et al., 2007). 
The CRB complex is formed by the transmembrane protein CRB, associated to PALS1 
and PALS1-associated tight junction protein (PATJ) in the cytoplasmatic side. The 
CRB complex is required to establish the apical membrane, it is essential for the tight 
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junction assembly (Bulgakova and Knust, 2009). CRB was first identified in 
Drosophila as a sub-apical localizing factor, and CRB mutant exhibited a disorganized 
epithelium (Bachmann et al., 2001). 
In Drosophila embryos CRB interacts with Stardust (homolog of  PALS1) and they are 
involved in zonula adherents junction formation. Three human homologs of CRB 
(CRB1-2-3) have been identified and characterized as polarity establishment factors, 
and they exert an important role in polarity maintenance both in normal and 
pathological conditions. In fact its loss causes several pathological alterations, for 
example retinal dystrophies (Richard et al., 2006). 
In addition to Par and CRB complexes, epithelial polarization requires a third complex 
Scribble (SCRIB), which defines the basolateral plasma domain identity. This complex 
is involved in regulating adherent junctions integrity (Laprise et al., 2004), it consists on 
three proteins SCRIB, lethal giant larvae homologue (LGL) and discs-large homologue 
(DLG) and it is essential for cell-cell contact (Khursheed and Bashyam, 2014).  
SCRIB was first identified in Drosophila as a regulator of epithelial cell septate 
junctions. To date, a single mammalian homologue of SCRIB (Scrb1) has been 
identified, whereas four DLGs, DLG1-2-3-4, and two LGL, (Hugl1-2) have been 
described (Humbert et al., 2008). DLGs are PDZ-containing (PSD-95, Dlg, ZO-1) 
membrane-associated guanylate kinase (MAGUK) proteins implicated in regulation of 
membrane protein targeting. Moreover, other DLG-related proteins have been 
described, in particular DLG5 even maintaining a high homology with DLG seems to 
be distinct to DLG family and evolutionary conserved (Nechiporuk et al., 2007). 
The coordinated action of these three complexes is required for obtaining polarized 
cells. CRB and PAR cooperate together in establishing the apical domain, inducing the 
assembly of TJ, whereas SCRIB defines the basolateral plasma membrane domain by 
inducing the adherens junctions. The establishment of cell polarity depends on 
antagonistic interactions between the polarity complexes, it starts through their 
interactions with cytoskeleton and adhesion proteins, that in turn regulate each other 
spatiotemporally (Martin-Belmonte and Perez-Moreno, 2011).  
Epithelial cells start to be oriented through the adhesion of integrin with extracellular 
matrix, establishing the basal surface; then cells start to extend filopodia, to contact 
neighboring cells and begin to form a layer. At the initial stage there is a primordial 
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kind of adhesion made by a mixture of adherent and tight junction proteins such as 
afadin, E-Cadherin and junctional adhesion molecule A (JAMA), recruited thanks to 
PAR3. Only later AJs and TJs separate by exclusion of PAR3 from the TJs, through 
negative regulatory interaction mediated by an complex phosphorylation network. 
Indeed, at intermediate stages of polarization aPKC activates and promotes PAR3 
exclusion from primordial adhesions. PAR3 exclusion from both the PAR6–aPKC and 
CRB complexes, establish the apical-lateral border and the apical membrane.  
The SCRIB complex defines the basolateral plasma membrane domain by antagonizing 
the PAR and CRB complexes; aPKC inhibits the Scribble complex by phosphorylation 
of Lgl, which then prevents Lgl from associating with the apical cortex (Hutterer et al., 
2004). Lgl also associates with the PAR-6/aPKC complex and competing with PAR3 
sequestering the Par complex from apical region and thus Lgl inhibits its association 
with the cortex, and probably its kinase activity (Wirtz-Peitz and Knoblich, 2006). This 
suggests a mutual antagonism by which Lgl inhibits aPKC laterally, and the Crumbs 
complex (Crumbs/PAR-6/aPKC) inhibits Lgl apically. 
Figure 3. Execution of the epithelial polarity programme. The epithelium is the first tissue to appear during 
development. 
A In mammalian embryos, an epithelium arises when morula (8-16 cells stage embryo) cells compact to form a 
lumen and epithelial cadherin (E-cadherin) is expressed to form a blastocyst.  
B Schematic representation of a full polarized epithelial cell, see the text for detail. (adapted from(Rodriguez-Boulan 
and Macara, 2014) 
A 
B 
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Moreover, a recent work shows how cells respond to basal membrane contact in 
mammary tissue, integrin signaling mediated by IL-K controls the delivery of apical 
components to the correct surface by polarizing microtubule cytoskeleton and thereby 
governs the orientation and lumen formation (Akhtar and Streuli, 2013).  
Epithelial cell polarity and cancer 
In addition to the essential role in maintain cells tightly associated, Epithelial cell 
polarity is needed to correctly orchestrate the signaling pathways that regulate epithelial 
proliferation. Polarity disruption rent cells unresponsive to growth inhibition, 
senescence and apoptosis. Accumulating evidences have unmasked the crucial role of 
polarity regulator in cancer, malignant tumor cell lose their polarity, and this is likely to 
play a role in tumorigenesis and metastasis (Martin-Belmonte and Perez-Moreno, 
2011). Apical-basal polarity exerts two essential cancer-related functions; first - it 
regulates maintenance of cell-cell adhesions, second - it controls asymmetric cell 
division. 
To date several reports have connected cancer and polarity complexes, suggesting their 
tumor suppressive roles (Royer and Lu, 2011).  
A lot of evidences have described SCRIB as a tumor suppressor, starting from the 
observation that its expression is sometimes lost in advanced tumors, or the protein is 
frequently mislocalized in human breast cancer. Moreover, SCRIB lost have been 
connected to apoptosis inhibition and enhanced MYC mediated transformation in 
mammary three-dimensional cultures (Zhan et al., 2008). It has been also shown that 
SCRIB directly interacts and inhibits ERK activity, thus its loss frequently seen in 
cancer can result in an increase of oncogenic RAS signaling (Pearson et al., 2011). 
Also CRB3 has been identified as a tumor suppressor gene, in fact several reports show 
that CRB3 expression is repressed both in vivo and in vivo and this has been correlated 
with impaired tight junction formation, lost of apical-basal polarity and contact 
inhibition (Aigner et al., 2007).  
Less clear is the expression of PAR complex during transformation, however there are 
some evidences, for example experiments showing that when overexpressed, as 
frequently occurs in breast cancer, the well known oncogene ERBB2 can bind to PAR6-
aPKC and sequester them from PAR3, this event leading to PAR complex disruption 
and compromised tight-junction formation (Aranda et al., 2006). Nevertheless, PAR 
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complex plays a decisive role during epithelial to mesenchymal transition (EMT), a key 
phenotypical change during cancer aggressiveness acquisition (see below); upon 
transforming growth factor beta (TGFβ) stimulus, PAR can dampen its signaling, 
interfering with RhoA mediated TJs stabilization. In fact, PAR is able to recruit and 
activate the E3 ubiquitin ligase SMURF1 inducing RhoA degradation (Wang et al., 
2006). 
Another important cue that connects cancer to epithelial cell polarity is PAR4, also 
named LKB1. LKB1 is a master regulator kinase that controls, among others, AMP-
activated protein kinase (AMPK), a very well known regulatory kinase of cellular 
metabolism and cancer. AMPK also controls polarity by regulating tight junction 
assembly, and by phosphorylating MAP/microtubule affinity-regulating kinase 
MARK/PAR family proteins AMPK can lead to microtubules destabilization (Partanen 
et al., 2009).   
Moreover also PTEN, a well studied tumor suppressor, plays an essential role in 
controlling cell polarity establishment. In fact, as mentioned above, PTEN inducing 
local generation of PIP2 in apical membrane, regulates the recruitment of PAR complex 
(Tanos and Rodriguez-Boulan, 2008). 
Together PTEN and AMPK play a double role in cancer, through their well known 
pathway, since they regulate a mammalian target of Rapamicyn (mTOR), the central 
regulator of cell cycle progression, proliferation, cell growth and thus cells 
transformation; but also they can foster cancer transformation directly, by altering 
epithelial cell polarity, regulating distribution of phosphatidylinositol lipids along the 
membrane.  
Epithelial cell polarity and cancer stem cell 
The maintenance of epithelial tissue is guaranteed by the presence of stem cells. Adult 
stem cells are able to self renew, as all the other cells of the tissue they are polarized, 
but they can divide in two alternative ways, symmetrically to create two stem daughter 
cells, or asymmetrically by reorienting the spindle in order to generate a differentiated 
cell and a stem cell, to maintain the stem pool (Knoblich, 2010).  Asymmetric cell 
division has been demonstrated to occur in various epithelial tissue including mammary 
gland, lung and epidermis (Lechler and Fuchs, 2005). Some evidences coming from 
different kind of tumors, including colon, prostate, lung and breast (Visvader, 2011) 
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indicate that alteration in normal adult stem or progenitor cells can initiate cancer 
transformation. The cancer stem cells (CSC) are a subpopulation of neoplastic cells that 
have been found in a wide range of cancer (colon, pancreas, prostate, brain and breast) 
(Reya et al., 2001), they are  defined experimentally by the ability to generate tumor 
when inoculated in recipient host mouse, and for that they have been also named us 
“tumor-initiating-cells” (Clarke and Fuller, 2006; Reya et al., 2001).  
Two different theories on tumor-initiating-cells have been postulated (Figure 4). One 
relies on a clonal expansion model, which postulates that cancer origins from normal 
differentiated cells, that during transformation undergo increased mutation rate 
reacquiring stem-like features, such as the self renewal capability. The other model 
proposes that transformation occurs in progenitor or tissue stem cells. Interestingly, 
epithelia polarity complexes are also involved in a mitotic control of epithelial stem 
cells by regulating distribution of cell fate determinants (such as NUMB) and 
orchestrating the correct orientation of a mitotic spindle. Deregulation of adhesion and 
polarity complexes leads to misoriented cell division, increasing self-renewal and thus it 
controls both stem cell numbers and differentiation (Martin-Belmonte and Perez-
Moreno, 2011). Centrosomal and apical protein play a central role in this process, by 
regulating each other (Rebollo et al., 2007). Study conducted in Drosophila has shown 
that centriole separation is regulated by several kinases, among them an important role 
is exerted by aurora kinase A (AuRA)  and polo kinase (Lukasiewicz and Lingle, 2009). 
Especially, during the prophase of a cell cycle AurA is able to phosphorylate PAR6, in a 
complex formed by PAR6-aPKC-LGL, this event provokes aPKC activation that in turn 
phosphorylate LGL causing it exclusion from the complex and allowing the association 
with Bazooka (PAR3 homologous), promoting subsequent phosphorylation and apical 
exclusion of the cell fate determinant NUMB. The importance of this pathway is 
supported by the observation that in Drosophila AUR mutant embryos have centrosome 
and spindle defects (Wirtz-Peitz et al., 2008). Additionally, in a parallel pathway, DLG 
can interact with PINS and oriented microtubules kinesin (KHC73) and induces 
asymmetrical spindle orientation (Januschke and Gonzalez, 2010).  
In mammals, similarly to Drosophila, the interaction between the PAR complex and 
DLG is a key event for spindle orientation and stem cells propagation. In vitro 
experiments show that an important role is accomplished by CdC42, that recruits the 
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PAR6-aPKC complex in an apical cortex allowing its activation. During mitosis 
intersectin2 that also localized in the centrosome, interacts with Guanine nucleotide 
exchanging factor TUBA and they together control the CdC42 recruitment and 
activation (Rodriguez-Fraticelli et al., 2010). 
 
Figure 4. Stem cells and cancer theories. 
A The postulated theories about the cell-of-origin that initiates tumors propose that cancers arise fromtissue-specific 
stem cells or progenitor cells. Stem cells divide during the lifetime of an organism and therefore have the potential to 
accumulate harmful mutations. Another theory proposes that tumours arise from normal cells within epithelial tissues 
that abnormally acquire the capability of self-renewal 
B Asymmetric segregation of cell fate determinants regulates the reorientation of the mitotic spindle in Drosophila 
melanogaster neuroblasts and in mammalian epithelial cells. Loss of asymmetric cell divisions in stem or progenitor 
cell compartments, or alterations in differentiated cells, may lead to their proliferation through symmetric cell 
divisions, which would promote their expansion. (Martin-Belmonte and Perez-Moreno, 2012).  
  
In addition, other factors can influence spindle orientation during stem cell divisions. 
Proteins that directly or indirectly associate with microtubules are surely involved in 
positioning of spindle, among them there are some well known tumor suppressor genes 
like p53, LKB1, adenomatous polyposis coli (APC), WNT, von Hippel-Lindau and 
adhesion molecules, such as E-cadherin. 
A 
B 
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Epithelial-mesenchymal transition, cancer stem cell, and cancer 
During cancer development epithelial cells may undergo a transdifferentiaton process, 
loosing many of their features and acquiring properties typical of mesenchymal cell, 
which include enhances migratory capacity, invasiveness, elevated resistance to 
apoptosis and increased production of extracellular matrix. these series of events is 
called ephitelial-to-mesenchymal transition (EMT) (Figure 5).  
EMT program plays crucial roles in differentiation of tissues and organs. The 
conversion of an epithelial to a mesenchymal cell requires complex changes in cell 
architecture and behavior; it involves profound phenotypic changes that includes loss of 
cell-cell adhesion, loss of cell polarity, and acquisition of migratory and invasive 
properties. 
During embryonic development different wave of EMT occurs, for example EMT is 
essential for gastrulation for mesoderm formation; or during delamination of neural 
crest cells from dorsal neural tubes. 
Also, later in development, EMT is involved in cardiac valve formation, which is 
derived from endothelial cells of endocardium that undergo EMT. 
In adults, a process similar to EMT occurs as a physiological response to injury - 
keratinocytes present at a border of a wound recapitulate all phenotypic changes and 
undergo EMT. Similar signaling pathways govern EMT also during pathological 
process like organ fibrosis, and cancer progression. In fact, EMT confers to cancer cells 
the mesenchymal state associated with a capability of cells to migrate to distant organs, 
maintain stemness, and develop metastasis. 
The loss of cell-cell junctions, and in particular E-cadherin expression is considered the 
crucial event. 
EMT is triggered by interplay of extracellular signals, including components of the 
ECM, such as collagen and hyaluronic acid, as well as soluble growth factors, such as 
members of the TGFβ and fibroblast growth factor (FGF) families, epidermal growth 
factor (EGF). Receptor-mediated signaling in response to these ligands triggers the 
activation of intracellular effector molecules, such as members of the small GTPase 
family - Ras, Rho and Rac - and members of the Src tyrosine-kinase family. These 
effectors orchestrate the disassembly of junctional complexes and the changes in 
cytoskeletal organization that occur during EMT.  
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The activation of signalling pathways results in transcriptional reprogramming thanks to 
the activation of transcriptional master regulators such as SNAIL, SLUG, TWIST and 
ZEB, which in turn regulate the changes in gene-expression patterns that underlie EMT. 
New player identified in EMT are microRNA, in particular miR-200 family members, 
that by downregulating ZEB factor inhibits EMT activation.  
Although the key events of EMT rely on transcriptional direct repression of E-cadherin, 
there is also the simultaneous repression of the transcription of several other junctional 
proteins, including claudins and desmosomes, which facilitate the general 
dedifferentiation program.  
Figure 5. Epithelial Plasticity in Invasive Growth Program  
Epithelial cell polarity represents a barrier to the later stages of tumor development. Apical–basal polarity is involved 
in the formation and maintenance of the AJs. Decreased expression of core polarity proteins is linked to weakening or 
disruption of the AJs, thereby leading to EMT and potential malignancy. Recent evidence suggests that TGFb, under 
certain conditions, can induce EMT in epithelial cells in conjunction with loss of cell polarity (Royer and Lu, 2011).  
 
Increasing amount of evidences show that EMT in cancer progression affects not only 
metastatic events, but also other processes highly relevant in tumor progression. Indeed 
it has been demonstrated that EMT confers to cells enhanced resistance to cell death and 
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senescence, TWIST-1 and -2 prevent cellular senescence induced by tumor suppressors 
p16/INK4a and p21.  
Moreover recent evidences show that cells undergoing EMT acquire stem cell-like 
properties. In human mammary epithelial cells expression of EMT-inducing 
transcription factor such as TWIST, SNAIL, ZEB1, Ras, Her2/Neu or treatment with 
TGF-β increase the number of stem-like cells, defined by an antigenic profile 
CD44highCD24low, a gene expression pattern, capability to form mammopheres in 
culture and tumors in xenograft. Conversely, genes typical to mesenchymal state 
(TWIST, SNAIL, ZEB2, fibronectin, vimentin) have increased expression in mammary 
stem-like cells.  
EMT and acquisition of CSC feature have been associated with increase in tumor 
aggressiveness. The affected cells show increase resistance to apoptosis and they 
develop resistance to various treatments, both chemoresistance and radio-therapy, that 
are effective in eliminating tumor bulk, but fail to eliminate CSC that cause tumor 
relapses (Dontu and Wicha, 2005). 
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P53 and cancer 
All cancers carry somatic mutation in their genomes. Genomic instability constitutes 
one of the most important enabling capability and it has an essential role during 
transformation and dissemination (Hanahan and Weinberg, 2011); defects in genome 
maintenance and repair, generating random mutations, could foster by chance 
acquisition of favorable mutation for tumor progression. 
Mutations that are clearly linked to oncogenesis and confer clonal selective advantage 
are called driver mutations.  
In 2012 a comprehensive study of mutational states coding genes and microRNAs tried 
to identify driver mutation for breast cancer. Somatic driver mutation were identified in 
40 genes, previously implicated in breast cancer development including AKT1, 
BRCA1, CDH1, GATA3, PIK3CA, PTEN, RB1 and TP53 (Stephens et al., 2012).  
They include PI3K/AKT/mTOR pathway, already involved in cell growth and 
metabolism regulation. Mutation in genes encoding PI3K catalytic or regulatory 
subunits (PIK3CA, PIK3CB, PIK3R1) are very commonly found in breast cancer cells; 
but also mutations in PI3K downstream effectors like AKT1 and AKT2. 
Moreover in the same pathways frequently mutations have been described in the 
phosphoinositide phosphatase PTEN, a PI3K inhibiting enzyme, resulting in promoting 
tumor formation due to its loss-of-function and upregulated PI3K activity (Yuan and 
Cantley, 2008). 
Frequent mutations occurs in tumor suppressor genes involved in DNA repair, such as 
BRCA1 and BRCA2, and they result in the impaired ability to repair breaks in the DNA 
double-strand and thus enhanced genome instability but also directly in uncontrolled 
proliferation of mutated cells (Vidarsson et al., 2002). 
Moreover in breast cancer frequently there are defects in the expression of RB protein 
or impaired activity of cell-cycle regulatory protein p53, promote accumulation of DNA 
damage and out-of-control cell proliferation (Hanahan and Weinberg, 2011). 
The p53 tumor suppressor pathway 
P53 was first identified in 1979, as a protein associated with simian virus 40 (SV40) 
large antigene T and for some years it was generally known as an oncogene (Kress et 
al., 1979; Lane and Crawford, 1979; Linzer and Levine, 1979). Only later by comparing 
sequences of various p53 clones it became clear that in cancer mutations in TP53 are 
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frequent and the encoded variants of p53 are different from that one present in normal 
cells. 
P53 is a transcription factor, with a modular structure formed by distinct functional 
domain: 
• N-terminal transactivation domain (amino acid aa 1-61), interacting with the 
transcriptional machinery (Unger et al., 1993); 
• Proline reach domain (aa 64-93), required for p53 stabilization;  
• DNA binding domain (aa 93-292), that recognizes and binds the responsive 
element on DNA, and proteins that affect positively or negatively p53 activity 
such as MDM2 or 53BP1 respectively (el-Deiry et al., 1992); 
• Oligomerization domain (aa 325-355), essential for tetramer formation that 
represents the active form of p53 (Shieh et al., 1999); 
• C-terminal regulatory domain, containing residues post-translationally modified 
involved in modulation of its stability (Kruse and Gu, 2009). 
p53 represents sensor of a great variety of cytotoxic and genotoxic stress, it is a central 
node of a complex network, in which convey several signals originate both from 
external factors (such as γ-radiation, UV-light, DNA damaging agents etc) or internal 
once (oncogene activation, high levels of reactive oxygen species, ribonucleotide 
depletion etc.) (Kruse and Gu, 2009) (Figure 5). This kind of stress may compromise 
genomic stability and promote neoplastic transformation; it provokes post-translation 
modification on p53 leading to p53 stabilization and activation.  
P53 is mainly regulated at the protein level, which is maintained low primarily through 
MDM2 E3-ubiquitin ligase and by the proteasome system (Momand et al., 1992). 
Once activated, p53 acts essentially as a transcription factor that promote a coordinated 
expression of target genes inducing generally growth arrest, senescence or cell death. In 
proliferation control, one of the strongest p53-induced target gene encodes for the cyclin 
dependent kinase inhibitor p21 (el-Deiry et al., 1994), blocking cell cycle in G1 phase. 
This response is also accomplished by induction of other p53 target genes such us 14-3-
3 sigma and GADD45 that induce cell cycle arrest in G2-phase (Hermeking et al., 1997; 
Kastan et al., 1992). In controlling of cell cycle, the transcriptional program induced by 
p53 includes also miR-34 family. miR‑34 contributes to p53 activity downregulating 
hundreds of mRNAs, which are enriched in cell cycle regulators, including CDK4, 
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CDK6, cyclin E2 and E2F3 that have been experimentally validated as miR‑34 targets. 
Moreover, also the anti-apoptotic protein BCL2 and the deacetylase SIRT1 were shown 
to be downregulated by miR‑34 in several cell types, consistent with a role for miR‑34 in 
p53-mediated apoptosis (Bommer et al., 2007). The homologous miRNAs, miR-192 
and miR-215 have also been found upregulated in a p53-dependent manner and, like 
miR-34a, they induce cell cycle arrest, by acting on several transcripts of proteins that 
regulate G1 and G2 checkpoints (Braun et al., 2008). 
According to cell type, the kind of stress and its extent activation of p53 may result in 
apoptosis rather then cell cycle arrest. P53 is able to orchestrate an apoptotic response 
by transactivating pro-apoptotic genes, such as Bax, Bid, Puma, Noxa belonging in the 
Bcl-2 family (Miyashita et al., 1994b; Nakano and Vousden, 2001; Oda et al., 2000; 
Sax et al., 2002), and by repressing anti-apoptotic genes such as Bcl-2, Bcl-XL 
(Miyashita et al., 1994a; Miyashita et al., 1994b). Moreover, in apoptotic induction, also 
a non-transcriptional activity has been described, by the capability of p53 to directly 
interact members of Bcl-2 family at a cytoplasmic level, and directly inducing outer 
membrane permeabilization, release of cytochrome c, and apoptosis (Mihara et al., 
2003). Recently, it has also been described a role of p53 in regulating necrotic cell death 
upon oxidative stress, Ca2+ and ROS induce p53 activation and its mitochondrial 
translocation inducing VDAC oligomerization and PTP pore formation causing  H2O 
intake, swelling of mitochondria and necrosis (Vaseva et al., 2012) 
But p53 is not involved only in promoting cell death; induction of DNA damage by 
oncogene activation or in response to telomere dysfunctions activates p53 and induces 
senescence (Chen et al., 2005; Ventura et al., 2007).  
In addition to these activities, in the last years has been demonstrated that p53 exerts an 
important role in a wide range of processes, such as metabolism (Kanfi et al., 2008), 
autophagy (Tasdemir et al., 2008), fertility (Hu et al., 2007), and stemness (Gatza et al., 
2008).  
But the main importance of p53 pathway in tumor suppression is strongly highlighted 
by the observation that mutations of p53 are very frequent in human cancer 
 Mutant p53 
According to COSMIC (Catalog of Somatic Mutation in Cancer, 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic) TP53 gene is mutated in 
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around 31% of human tumor. In breast cancer it is mutated in ∼35% of total breast 
cancer, but this percentage is increased to 54% in TNBC (Polyak and Metzger Filho, 
2012) (Figure 6). 
 
Figure 6. The distribution of reported missense mutations along the p53 sequence.  
The six most common hotspot mutations are highlighted: R175 and R273are DNA‐contact mutations, G256 and 
R249 are locally distorted mutants, R175 and R282 are globally denatured mutants. The domain architecture of p53 is 
aligned below; the numbers on horizontal axis are codon/amino acid numbers. Adapted from (Freed-Pastor and 
Prives, 2012) 
 
Moreover genetic mutations cause Li-Fraumeni syndrome, characterized by cancer 
predisposition associated with a large variety of tumor type, with 25% incidence of 
breast cancer (Olivier et al., 2010). 
Interestingly, inactivation of p53 accounts mostly for missense mutations, which 
represent more than 70% of total TP53 mutations in cancer (IARC TP53 Database, 
http://p53.iarc.fr) As results of this spectrum of mutation, in the vast majority of tumors 
cells are able to translate full-length p53 proteins that differ from the wild type (wt) by 
single aminoacids. Most of this missense mutation occurs within the DNA binding 
domain (DBD) and particularly six “hot spot” mutated residues have been identified 
(Hollstein et al., 1991). Missense mutation on the p53-DBD are classified in two main 
categories according to the structural alteration and stability that they have on p53 
protein: there are distinguished in DNA-contact mutation, that impinge on residues 
directly involved in DNA-binding (e.g. R248Q and R273H); and conformational 
mutation that cause local (e.g. R249S) or global (R175H) conformational alteration on 
the protein structures (Bullock and Fersht, 2001). 
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Unlike other tumor suppressor genes, which are predominantly inactivated by deletion 
or truncation, the missense mutations on p53 cause a strong functional impact. 
First, mutations cause abrogate the tumor suppressor function of p53 (a phenomenon is 
called Loss of Function; LOF) resulting in absent activation of downstream effector, 
and loss of normal checkpoint control (Figure 7) (Brosh and Rotter, 2009). 
Figure 7. Schematic representation of the functional impacts of TP53  mutations. LOF (loss of function); DN 
(dominant-negative effects); GOF (gain of function). (Brosh and Rotter, 2009) 
 
In addition, most of mutant p53 (mut-p53) forms are able to oligomerize with the wild-
type protein encoded by the second allele, inhibiting its function, forming a 
heterotetramer unable to DNA binding (Dominant negative Function) (Figure 7) (Brosh 
and Rotter, 2009). 
Finally several mutations were shown to confer new oncogenic functions to mut-p53 
(Gain of Function; GOF), (Figure 7) totally independent on wt-p53, and actively 
contribute to various aspects during tumor progression (Oren and Rotter, 2010).  
Multiple evidences both in vitro and in vivo have demonstrated the role of mutant p53 
in tumor. Li-Fraumeni mouse models harbouring R172H mutant missense p53 
(corresponding to human R175H) compared to knock-out mice, have shown a different 
tumor spectra and increase metastasis rate (Olive et al., 2004) 
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Mutation in TP53 have been directly associated with cell transformation and with a 
wide range on oncogenic function, e.g. interference with apoptosis (Li et al., 1998), 
enhanced drug resistance, genomic instability, and increase of aggressive features such 
as migration and invasion (Figure 8).  
 
Figure 8. Selected oncogenic properties of mutant p53 and their underlying mechanisms. Mutant p53 involvement 
in processes associated with breast cancer development. Mutant p53 is known to affect multiple oncogenic processes. The asterisks 
(*) indicate oncogenic mechanisms known to be important for breast cancer, linked to p53 gain-of-function in other tumors, but not 
yet directly tested for mutant p53 dependence in mammary carcinoma cells or mouse models. (adapted from (Walerych et al., 2012).  
 
Biological manifestation of mutant-p53 
Cell transformation and apoptosis inhibition  
Both in human and in mouse it has been demonstrated that mut-p53 in respect to its 
counterpart wt-p53 can transform p53-null cells, enabling them to form colonies in soft 
agar, or to form tumor in mice (Dittmer et al., 1993). And vice versa in a transformed 
system with mut-p53, its down-regulation is sufficient to reduce or abrogate 
tumorigenicity (Bossi et al., 2006; Bossi et al., 2008). 
In promoting cell transformation mut-p53 cooperates with the oncogene K-Ras, in vivo 
data demonstrates that such mice have increased tumor formation, accelerated disease 
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progression, and elevated rates of metastasis, when compared to p53-null mice (Caulin 
et al., 2007).  
Overexpressed p53 is able to augment cell proliferation both in vitro and in vivo. This 
also relies in the acquired resistance to pro-apoptotic signals. One of the first identified 
evidence showed that in leukemic cells p53 suppress c-Myc induced apoptosis. Mut-p53 
could also confer the selective advantage in competitive microenvironment, protecting 
cells against apoptosis due to growth factor deprivation (Peled et al., 1996). 
Drug resistance  
Strictly interconnected with apoptotis inhibition, mut-p53 overexpression rend cell able 
to resist of killing action of anticancer agents, such as doxorubicin, cisplatin, etoposide, 
and moreover p53 knockdown can restore their effect. Chemoresistance is correlated 
with the ability of mut-p53 to bind p73 interfering with its pro-apoptotic activity (Li and 
Prives, 2007). Moreover, mutant-p53 dependent activation of MDR1 further enhanced 
chemotherapy resistance, thus in tumors that harbor p53 mutations, ablation of mut-p53 
GOF should increase chemotherapy effect. 
Genomic instability  
Several reports shown that mut-p53 disrupts normal spindle checkpoint control, 
resulting in chromosomal aberration and polyploidy (Gualberto et al., 1998). In 
addition, mut-p53 interferes with DNA repair, by attenuating Base excision  repair 
(Offer et al., 1999), by binding topoisomerase I, fostering DNA rearrangements and 
aberrant homologous recombination, but above all it inhibits double strand repair 
system. Mut-p53 binds Mre11 preventing its recruitment at level of dsDNA breaks, 
avoiding Rad50-NBS1 binding and thus ataxia teleangectasia mutated (ATM) 
dependent DNA damage activity (Song et al., 2007). 
Cancer aggressiveness, cell migration and invasion 
Mut-p53 knock-in mice proof that the presence of mut-p53 in respect to p53-null mice 
increase tumor aggressiveness, and display higher metastatic potential (Attardi and 
Jacks, 1999). 
In vitro experiments indicate that mut-p53 increases cell migration and invasion, also by 
cooperating with oncogenic pathway such as Ras or TGF-β (Adorno et al., 2009). 
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Indeed mut-p53 was found to facilitate cell migration and invasion enhancing 
EGFR/integrin receptor (Muller et al., 2009).  Important in promoting this GOF 
phenotype is the inhibition of anti-metastatic role of p63, both impinging on TGF-β and 
EGFR/integrin receptor pathway. 
EMT and Epithelial cell polarity 
Recently it has been also demonstrated that mut-p53 can induce EMT in several cancer 
model, cause Slug and Twist activity modulation or CCN-5/WISP2 inhibition (Dhar et 
al., 2008). EMT also induces a reprogramming associated to stem cell characteristics 
mut-p53-dependent (Mizuno et al., 2010). 
Furthermore mut-p53 trough EMT regulation coordinate three-dimensional growth of 
breast cancer cell disrupting their polarity, and mut-p53 depletion in aggressive breast 
cancer-derived cells reverts malignant structured into more normal acinus-like 
structures acting on mevalonate pathway (Freed-Pastor et al., 2012).  
Mechanism of mutant-p53 Gain of Function 
Missense mutation that occurs on p53, especially in DBD disrupts its ability to bind p53 
consensus. The molecular basis of how mutant p53 regulates its own gene targets 
involved in different aspects of tumor progression (such as proliferation, inhibition of 
apoptosis, chemioresistance, metabolism) is not yet very well understood, even-though 
changes in interaction with others proteins  (mostly transcription factor, but also 
proteins not directly related in gene expression regulation) affect gene expression (Kato 
et al., 2003).  
Moreover, accumulating evidences show that many loci missing for wt-p53 responsive 
elements are directly induced by mut-p53, this suggests that mut-p53 acquires distinct 
DNA-binding and transactivation activities.  
Several in vitro evidences show that mut-p53 retains the ability to bind DNA with high 
affinity, probably in specific non-B sequence or in attachment region with nuclear 
matrix (Will et al., 1998).  
As gain of function, mut-p53 can bind to transcription factor to enhance or prevent their 
activities. Among them interaction of mut-p53 with NF-Y results in activation of gene 
involved in cell cycle promotion (such as cyclin and kinase cyclin dependent), inducing 
growth. Until now, a lot of mut-p53 partner have been identified, e.g. Sp1, NF-kB, 
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VDR (Stambolsky et al., 2010)that upon mut-p53 interaction increase expression of 
their targets genes; SREBP promoting mevalonate pathway gene expression (Freed-
Pastor et al., 2012); or Est-1 that is directly involved in MDR1 transcription and 
chemioresistance (Sampath et al., 2001). 
But above all, mut-p53 has been demonstrated to bind with member of its family, p63 
and p73, preventing their binding to DNA responsive elements and avoiding anti-
metastatic or pro-apoptotic, respectively, activity. Mouse models confirm this very 
important role; in fact mice heterozygous for p63 or p73 develop a very similar spectra 
of tumor and metastasis to those that arise in p53-knock in mice (Flores et al., 2005). 
More and more evidence are been accumulating about mut-p53 GOF, recently for 
example it has been shown that certain mut-p53 form prion-like aggregates that 
contribute to binding and inhibition of p53 family members (Ano Bom et al., 2012).  
Lastly, as already mentioned, mut-p53 can interact with other protein non-directly 
involved in transcription, such as MRE11 (Song et al., 2007) or Topoisomerase1 (Liu et 
al., 2011) both resulting in enhanced genomic instability. 
Furthermore, besides regulating the transcription of many different protein-coding 
genes, only a few recent studies have investigated miRNAs downstream of mutant p53. 
mutant p53 starts has been linked to micro-RNAs regulation and consequently to 
modulation of expression of their targets, connected with promotion of tumor 
phenotypes.  Examples include miR-155 (Neilsen et al., 2013),  miR-205 (Piovan et al., 
2012) and the very recent discovered let-7i (Subramanian et al., 2014) that are regulated 
in a p63-dependent manner and induce cancer cell migration and invasion. Moreover 
mut-p53 also promotes EMT through miR-130b repression by directly binding to the 
promoter of miR-130b (a negative regulator of ZEB1) and inhibiting its transcription 
(Dong et al., 2013). 
Nevertheless due to their importance miRNAs profiles associated with mut-p53 need to 
be further explored in order to understanding of the roles of p53 gain-of-function 
mutations in accelerating tumor progression and metastasis through modulation of 
miRNAs expression. 
Until today a lot of effort have been done to correlate gene expression signature (both 
protein coding genes and miRNAs) with mut-p53 status and outcome in cancer, in order 
to develop accurate prognosis tool and personalized therapy.  
Introduction 	  
	  	   	   30	  
Non coding RNA: an overview 
According to the central dogma of gene expression, the conventional view of gene 
regulation has been focus mostly in protein-coding genes, DNA transcribed into 
messenger RNAs, which in turn serve as template for protein synthesis. However, 
protein-coding RNAs are only 20000-25000 account for only 2-3% of whole human 
genome(Lander et al., 2001; Venter et al., 2001). The rapid development of high-
throughput sequencing technologies demonstrate that 98% of the “junk” DNA are 
transcribed as non coding RNAs (ncRNAs) (Louro et al., 2008). The RNA transcripts 
that do not code for protein provides a new perspective on gene regulation. 
It has become evident that the number and classes of RNAs encoded within the genome 
are much more extensive and complex than previously thought (Carninci, 2008; 
Carninci and Hayashizaki, 2007). 
Looking for their function, ncRNAs can be divided in two classes structural and 
regulatory ncRNAs. Structural ncRNA includes tRNAs, rRNA, and snoRNA. 
Based on their length regulatory RNA can be divided in at least 2 groups: 
• Long non coding RNA (>200 nucleotides); 
• Small non coding RNA including: Piwi interacting RNA (piRNA) (26-31 
nucleotides) and Short non coding RNA (endo-siRNA and miRNA) (22-23 
nucleotides). 
Nevertheless new classes are being discoverd year by year, e.g. there is also a less 
known class that includes medium-size RNA (50-200 nucleotides), or only recently 
described the tiRNA, the smallest known RNA (only 18 nucleotides) involved in 
transcription initiation (Gibb et al., 2011). 
Even if the ncRNA fraction was so far considered mainly useless, and the increasing 
number of non-protein coding transcripts has been suggested to be largely 
“transcriptional noise” (Dennis, 2002), there are now clear evidences that a significant 
proportion of ncRNAs have roles in a great variety of processes, including 
transcriptional regulation, chromosome replication, RNA processing and modification, 
messenger RNA stability and translation, and even protein degradation and 
translocation (Carninci and Hayashizaki, 2007; Carninci et al., 2005; Mattick, 2004). 
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Long non coding RNAs 
lncRNAs are transcripts from 200nt  up to 100 kilobases, usually transcribed by RNA 
polymerase II, spliced and polyadenylated. They can be transcribed, in intricate 
networks of overlapping sense and antisense transcripts (Birney et al., 2007). lncRNAs 
have been associated with a spectrum of biological processes, such as chromatin 
modification, transcription, post transcription processing (alternative splicing, nuclear 
import, mRNA decoy) (Wilusz et al., 2009). The ability of lncRNAs to bind to protein 
partners endow them with regulatory capabilities. Some common mechanisms of action 
have been described that can be resumed in 4 models. 
LncRNA can act as decoys that titrate away DNA-binding proteins such as transcription 
factors. LncRNAs may also act as scaffolds to bring two or more proteins into a 
complex or spatial proximity. LncRNAs may also act as guides to recruit proteins, such 
as chromatin modification enzymes, to DNA; this may occur through RNA-DNA 
interactions or RNA interaction with a DNA binding protein. LncRNA guidance can 
also be exerted through chromosome looping in an enhancer-like model, where the 
looping defines the cis nature and spread of the lncRNA effect (Wang and Chang, 
2011). 
The expression of many lncRNAs occurs during development, embryonic stem cell 
differentiation, and their aberrant expression have been linked to pathogenesis and 
tumorigenesis, even if up to date only a limited number of lncRNAs have been well 
characterize. 
Small ncRNAs 
small ncRNAs are more investigated, and the vast majority is involved in RNA 
interference mechanism (Hannon, 2002), leading to degradation of those mRNAs that 
form perfect hybrid with them (Mello, 2007). Small RNA function relies on the 
capability to bind Argonaute family protein, further classified in Ago subfamily and 
Piwi subfamily. 
smallRNAs are involved in almost every biological process, including development, 
cell differentiation, cell death, metabolism, transposon silencing and even antiviral 
defense (Filipowicz et al., 2008). 
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Accordingly to their origin, function and mechanisms of action small ncRNAs can be 
divided in three groups, endogenous short interfering RNAs (endo-siRNAs), miRNAs, 
and Piwi-interacting RNAs (piRNAs) (Kim et al., 2009). 
miRNAs are ∼22 nt long RNAs, involved in both protein-coding and non coding gene 
expression, by post-transcriptional silencing, or rarely by activation (Krol et al., 2010). 
miRNAs are generated form transcripts originated in the nucleus by RNA polymerase 
II. These primary transcripts contain hairpin structures excided by the action of two 
RNAse III enzymes, Drosha and Dicer (see below) (Kim et al., 2009).  
Endo-siRNAs  have been studied mostly in Drosophila, although they have also been 
found in mouse oocyte and in embryonic stem cells (Lee et al., 2004b). They are ∼21 nt 
long RNAs derived from long double stranded RNAs, in plants and in worms (were 
they have been discovered) they are produced by the action of RNA-depended RNA 
polymerase (RdRPs) (Ambros et al., 2003). In flies and mammalian endo-siRNA derive 
from retrotransposons and their biogenesis, unlike miRNAs, is depends only on Dicer 
RNA III activity. Some of them it has been shown to function as post-transcriptional 
regulators for target RNA (Czech et al., 2008; Okamura et al., 2008). 
piRNAs  are ∼24-31 nt long RNAs highly abundant in germ cells. Their biogenesis 
involves the germline specific Argonaute protein Piwi, AuB and Ago3 (Brennecke et 
al., 2007; Gunawardane et al., 2007) and does not depend on Dicer. Very little is known 
of this class of ncRNAs, in mammalian piRNAs are required for transposon silencing 
through heterochromatin formation or RNA destabilization in the germ line. (Vagin et 
al., 2006). 
microRNAs 
Only 20years ago, in 1993, Ambros and colleagues identified a small ncRNA, named 
lin-4, in embryonic development of C.elegans. This RNA is only 22 nt, it binds 7nt of 
complementary mRNA, partially blocking its protein translation (Ambros, 1989). 
Discovery of lin-4 opened a new window in expression regulation research. From that 
moment hundreds of miRNAs have been identified, they represent probably 1-5% of 
known genes, and have a crucial role in regulation of gene expression. In fact it seems 
that over one-third of human protein coding genes are predicted to be direct miRNAs 
targets (Bartel, 2004). 
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microRNAs biogenesis 
The transcription of most miRNA genes is mediated by RNA polymerase II (Cai et al., 
2004; Lee et al., 2004a), although a little group, associated with Alu repeats, can be 
transcribed by RNA polymerase III (Borchert et al., 2006). 
More than half of miRNA loci are transcribed as clusters from polycistronic transcript 
units (Lee et al., 2002). miRNA loci can be associated to non-coding regions or to 
protein-coding ones (intronic - 40% of cases, or in 10% of cases - exonic regions). 
In mammals most of miRNAs have multiple paralogues, derived from gene duplication; 
they share the same seed sequence and presumably target genes. However, the 3’ 
miRNA sequence also contributes to the miRNA-mRNA affinity, and thus paralogous 
miRNAs may have very distinct roles in vivo (Ventura et al., 2008). 
Figure 9. miRNA biogenesis pathway. Canonical 
miRNA (miRNA) genes are transcribed by RNA 
polymerase II (RNAPII) to generate the primary 
transcripts (pri-miRNAs). The initiation step 
(cropping) is mediated by the Microprocessor 
complex that generates ~65 nucleotide (nt) pre-
miRNAs. Pre-miRNA has a short stem plus a ~2-
nt 3′ overhang, which is recognized by the nuclear 
export factor Exportin5. On export from the 
nucleus, the cytoplasmic RNase III Dicer catalyses 
the second processing (dicing) step to produce 
miRNA duplexes. Dicer, TRBP or PACT and 
Argonaute (AGO)1–4 mediate the processing of 
pre-miRNA and the assembly of the RISC in 
humans. One strand of the duplex remains on the 
Ago protein as the mature miRNA, whereas the 
other strand is degraded. Ago is thought to be 
associated with Dicer in the dicing step as well as 
in the RISC assembly step.  
AGO2, which has robust RNaseH-like 
endonuclease activity, can support Dicer 
processing by cleaving the 3′ arm of some pre-
miRNAs, thus forming an additional processing 
intermediate called AGO2-cleaved precursor 
miRNA (ac-pre-miRNA) 
Non-canonical intronic small RNAs are produced 
from spliced introns and debranching. Because 
such small RNAs (called mirtrons) can derive 
from small introns that resemble pre-miRNAs, 
they bypass the Drosha-processing step. Some 
introns have tails at either the 5′ end or 3′ end, so 
they need to be trimmed before pre-miRNA 
export. m7G, 7-methylguanosine. (Kim et al., 
2009) 
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Little is known about transcription factors that regulate miRNAs expression. For 
miRNAs whose genes are located in exonic/intronic region of host genes the regulation 
is coordinated with the protein-coding gene expression. Conversely some miRNA loci 
reside in non-coding regions, these are autonomously expressed from their own specific 
promoter, thet are highly similar to those of protein-coding genes (Corcoran et al., 2009; 
Ozsolak et al., 2008). 
The primary transcripts (pri-miRNAs) are generated by PolII. They are several 
kilobases long and contain one or more stem-loop structures (Cai et al., 2004; Lee et al., 
2004a). 
In a canonical pathway (Figure 9), primary precursor (pri-miRNA) processing occurs in 
two steps, catalysed by two members of the RNase III family of enzymes, Drosha and 
Dicer, operating in complexes with dsRNA-binding proteins (dsRBPs), for example 
DGCR8 and transactivation-responsive and (TAR) RNA-binding protein (TRBP) in 
mammals. 
In the first nuclear maturation step, the Drosha–DGCR8 complex processes pri-miRNA 
into an ~70-nucleotide precursor hairpin (pre-miRNA) (Filippov et al., 2000). Drosha 
and DGCR8 toghether form a large complex (~650kDa) known as Microprocessor 
complex. DCGR8 is able to recognize the ssRNA-dsRNA junction and recruits Drosha, 
assisting it in the cleavage (~11bp away of this junction) (Gregory et al., 2004; Han et 
al., 2004). The microprocessor works co-transcriptionally (Morlando et al., 2008), and 
generates the pre-miRNA. that consist of a stem of ~33 base pair, and a terminal loop. 
This process already establishes the 5’of the mature miRNA and contains a 2-nt 
overhang at the 3’essential for nuclear export (Han et al., 2004; Zeng and Cullen, 2005). 
Some pre-miRNAs are produced from very short introns (mirtrons)  (Figure 9) as a 
result of splicing and debranching, thereby bypassing the Drosha– DGCR8 step. 
Export of pre-miRNA is mediated by Exportin5, that recognizes the stem with 2-nt 
overhang at the 3’ of the pre-miRNA, then binds a cofactor Ran in the nucleus, and after 
GTP hydrolysis releases the pre-miRNA in the cytoplasm (Kim, 2004; Zeng and Cullen, 
2004). 
Following nuclear export, pre-miRNAs are further processed by Dicer that cleaves near 
the terminal loop, assisted by TAR RNA-binding protein (TRBP) (Chendrimada et al., 
2005) and protein activator of the interferon induced protein kinase (PACT) (Lee et al., 
Introduction 	  
	  	   	   35	  
2006), yields an ~22-bp miRNA/miRNA* duplex (Knight and Bass, 2001). These two 
cofactors contribute also to RNA-induced silencing complex (RISC) formation. 
Following the Dicer cleavage, the ~22-bp RNA duplex is loaded into Ago protein, 
generating the RISC. Only one of the strands remains on Ago, this is the mature 
miRNA, whereas the other (miRNA*) is released and degraded. Generally, the retained 
strand is the one that has the less stably base-paired 5’(Schwarz et al., 2003). R2D2, a 
protein with two dsRBDs senses the thermodynamic inequalities and orientates Ago 
binding (Matranga et al., 2005). Human genome encodes 4 Ago proteins, they bind to 
miRNAs with almost the same affinity, but only Ago2 has RNaseH-like endonuclease 
activity (Liu et al., 2004). 
In mammals, AGO2, can support Dicer processing by cleaving the 3′ arm of some pre-
miRNAs, thus forming an additional processing intermediate called AGO2-cleaved 
precursor miRNA (ac-pre-miRNA) (Diederichs and Haber, 2007).  
miRNAs mechanism of action 
miRNAs are sophisticated gene expressions regulators, the mechanisms employed by 
miRNAs are still controversial, different evidences show that they induce target mRNA 
destabilization, translational repression, and in some rare cases even activation 
(Pasquinelli, 2012). 
miRNAs selectivity is mediated by nucleotide position 2-7 to the 5’ end of the miRNA, 
called a seed sequence, that recognizes and permits binding to target mRNAs (Bartel, 
2004).  
Multiple sites for the same miRNAs confer a more effective repression: in particular 
when miRNA binding sites are close to each other (10–40 nt apart), they can act 
cooperatively and their effect exceeds that expected from the independent contribution 
of two single sites (Grimson et al., 2007; Krek et al., 2005). 
miRNAs represses protein synthesis by multiple mechanisms. 
Translation initiation begins in Eukaryotes when the initiation factor eIF4F recognizes a 
5’mRNA cap. eIF4F is a subunit of the eIF4F complex that contains also eIF4A and 
eIF4G and its binding to mRNA recruits the ribosomal subunit 40S forming the 
preinitiation complex. This complex with initiation factors (eIFs) binds the 5’ cap and 
the cytoplasmic poly(A)-binding protein (PABP1) associated with the 3’, thus 
connecting the 5′ and 3′ ends of mRNAs and stimulating their translation. miRNAs can 
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act at different steps of translation (Carthew and Sontheimer, 2009). First, they allow to 
bypass the translational initiation, in fact AGO and GW182 (Eulalio et al., 2008) can act 
as eIF4E competitors. Other models propose that miRNA-induced silencing complex 
(miRISC) could prevent the mRNA circularization, pairing of the miRNA complex to 
target 3′ untranslated region (UTR) sites can result in deadenylation of the mRNA 
through recruitment of the CCR4–NOT complex by the (miRISC)-associated GW182 
proteins. Loss of the poly(A) tail causes dissociation of PABP1 and leads to degradation 
of the mRNA (Behm-Ansmant et al., 2006; Braun et al., 2011; Eulalio et al., 2008).  
 
Figure 10. Mechanisms of miRNA function. MicroRNAs (miRNAs) regulate gene expression through genetics 
multiple pathways. A complex of eukaryotic initiation factors (eIFs) binds the 5′ cap and the cytoplasmic poly(A)-
binding protein (PABPC), connecting the 5′ and 3′ ends of mRNAs and stimulating their translation by the ribosome. 
a. Perfect pairing between an miRNA and its target site induces endonucleolytic cleavage by AGO, leading to rapid 
degradation of the mRNA. b. Partial pairing of the miRNA complex to target 3UTR  sites can result in deadenylation 
of the mRNA through recruitment of the CCR4–NOT complex by the miRNA-induced silencing complex (miRISC)-
associated GW182 proteins. Loss of the poly(A) tail causes dissociation of PABPC and leads to degradation of the 
mRNA. c. The miRISC can also induce translational repression by blocking initiation via recruitment of CCR4–NOT 
by GW182. d. Translational repression can also be induced by the miRISC by inhibiting a step after initiation, such 
as promoting ribosome drop-off or stimulating proteolysis of the nascent peptide. e. miRNAs have also been shown 
to upregulate target expression under certain conditions through a mechanism that involves Argonaute and fragile X 
mental retardation protein 1 (FMR1) (Pasquinelli, 2012). 
 
Perfect pairing between a miRNA and its target site induces endonucleolytic cleavage 
by Argonaute (AGO), leading to rapid degradation of the mRNA, but whereas this 
mechanism is frequent in plants, in humans often miRNA-mediated mRNA degradation 
is not dependent on Ago-catalyzed mRNA cleavage, but rather on deadenylation, 
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decapping, and exonucleolytic digestion of the mRNA (Behm-Ansmant et al., 2006). 
Ago proteins are frequently associated in the cytoplasm to discrete cytoplasmic foci that 
often accumulate translationally inactive mRNAs, argonaute proteins and miRNAs 
(Jakymiw et al., 2005; Liu et al., 2005; Pillai et al., 2005). Additionally P bodies include 
many proteins implicated in miRNA function, such as GW182, the CAF1-CCR4-NOT 
deadenylase complex, decapping enzyme DCP2, decapping activators (e.g., DCP1, 
EDC3, Ge-1) and RNA helicase RCK/p54 (Decker and Parker, 2012; Eulalio et al., 
2007). Observation that miRNAs are also associated with polysome suggest that 
translation can be repressed by the miRISC also after initiation, such as promoting 
ribosome drop-off, promoting premature ribosome dissociation, or stimulating 
proteolysis of the nascent peptide (Nottrott et al., 2006; Orom et al., 2008; Vasudevan et 
al., 2007).  
Under certain circumstances, miRNAs have also been shown to upregulate target 
expression through a mechanism that involves Argonaute and fragile X mental 
retardation protein 1 (FMR1) (Nottrott et al., 2006; Orom et al., 2008; Vasudevan et al., 
2007). 
miRNAs and cancer 
In normal cells miRNAs are involved in maintaining a balance of a wide array of 
biological processes including differentiation, proliferation and apoptosis. miRNAs  
dysregulation can have profound cellular consequences, especially because of their 
pleiotropic effect on multiple mRNA target (Croce, 2008).  
Changes in miRNAs expression are a common feature of cancers and are often directly 
implicated in the carcinogenic process as oncogenes or tumor suppressors (Kasinski and 
Slack, 2011). miRNAs are involved not only in tumor development, but  also in each 
step of transformation and progression, angiogenesis and metastasis (Nicoloso et al., 
2009) both positively and negatively. For example a prometastatic role have been 
described for miR-10b, found downregulated in all breast carcinomas from metastasis-
free patients. miR-10b inhibits the translation of the homeobox D10 (HOXD10) mRNA, 
releasing the expression of the prometastatic gene RHOC, and it is promoted by the 
EMT inducer Twist (Iorio et al., 2005; Ma et al., 2007). 
Conversely, members of the miR-200 family and miR-205 have been shown to reduce 
cell migration and invasiveness by targeting ZEB transcription factors, known  EMT 
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inducer ((Gregory et al., 2008; Park et al., 2008) and PKCepsilon (Gandellini et al., 
2009).  
miRNA levels and functions can be affected by several mechanisms. Mapping of 
miRNA loci, thanks to new high-throughput techniques, unveils that hundreds of 
miRNAs map in human genome regions frequently involved in chromosomal 
alterations, deletions or amplifications in human cancers (Calin et al., 2004). It is 
conceivable that mutations affecting miRNAs or their functional interactions with 
oncogenes and tumor suppressor genes could contribute to tumorigenesis (Croce, 2008).  
Nevertheless, the causes that lead to altered expression of miRNAs remain still poorly 
understood.  
Figure 11. miRNAs are subject to genomic regulation.  a. allelic amplification (which is typical of oncogenic 
miRNAs results in decreased expression of target genes, including those targets with less miRNA affinity that may 
not normally be repressed. b. Genomic deletion (which is typical of tumour-suppressive miRNAs) enhances target 
gene expression. c. Single nucleotide polymorphisms (SNPs) in the miRNA can either create or destroy miRNA 
binding sites. This alteration in the miRNA changes the ability of the miRNA to bind to and repress target genes. In 
cancer, SNPs can alter the miRNA such that it now targets tumour-suppressive genes while losing its ability to target 
oncogenes (Kasinski and Slack, 2011). 
  
First, alteration of miRNA expression may derive from alterations of their genomic loci 
in tumors (deletions, amplifications etc) (Figure 11a-b) (Calin et al., 2004; Zhang et al., 
2006) or from epigenetic changes such as altered DNA methylation, as suggested by the 
fact that half of the genomic sequences of miRNA are associated with CpG islands.  
Typically for tumor suppressive miRNA, genomic deletions enhance target genes 
expression.  
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with myeloproliferative disease and a latent progression 
to AML58. A second system specifically evaluated the 
contribution of overexpressed iR-29a to B-CLL. When 
miR-29a was expressed in immature and mature B cells, 
there was an expansion of CD5+ B cells, mice presented 
with enlarged spleens, and roughly 20% of animals devel-
oped overt leukaemia and died late in life, suggesting that 
in this case miR-29a can predispos  cells to a ca cerous 
state59. The molecular mechanism probably involved 
direct translational silencing of the tumour-suppressive 
cell-adhesion molecule peroxidasin homologue (PXDN) 
by miR-29a (FIG. 1).
These data suggest that miR-29a functions as a 
tumour suppressor or oncogene, depending on the 
cellular context.
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LIN28. Models in which the miRNA processing 
machinery is perturbed give insight into the function 
of particular miRNA families, as observed in the 
LIN28-overexpressing strain. LIN28 is an RNA-binding 
protein that suppr sses the maturation of let-7 family 
miRNA precursors. In this way, a mouse model overex-
pressing Lin28 overcomes the technical challenges asso-
ciated with knocking out all 14 let-7 family members60,61. 
Because let-7 is a bona fide tumour suppressor62, loss 
of let-7 at the organismal level is predicted to predis-
pose animals to cancer. These studies, which focused 
on the role of LIN28 in development60 and glucose 
metabolism61, did not report any cancerous phenotypes. 
Whether overexpressing LIN28 at later timepoints can 
induce tumorigenesis or potentiate tumour-prone mice, 
such as those that overexpress activated Kras or Myc or 
that lack Trp53, remains to be determined.
DICER. In cancer, miRNA expression is frequently 
decreased63; defects in DICER or other miRNA pro-
cessing machinery could elicit such an effect (FIG. 2). 
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The first report describing a potential role of a miRNA in cancer, was the 
characterization of miR-15a and miR-16-1 as part of the 13q14 deletion, an event 
frequently occuring in chronic lymphocytic leukaemia (CLL) (Dohner et al., 2000) and 
in other malignancies including mantle cell lymphoma, multiple myeloma and prostate 
cancer. These two miRNAs act as tumor suppressors in vivo: by controlling 
proliferation, apoptosis and invasion through targeting oncogenes like BCL-2, 
CCDND1 and WNT3A (Bonci et al., 2008) 
Since these observations a similar mechanism has been shown for a lot of miRNAs, for 
example members of the let-7 family of miRNAs map to chromosome regions that are 
deleted in many tumors and were in fact found to be lost in different cancers (lung, 
breast, ovarian and cervical) (Calin et al., 2004)(Takamizawa et al., 2004).  
On the contrary, amplification of typical oncogenic miRNAs results in decrease of their 
target genes’ expression, including genes with low binding affinity that probably 
normally are not repressed. For example the oncogenic miR-155 and the miR-17–92 
cluster map to regions that are amplified in lymphoma and were found overexpressed in 
different tumors (Calin et al., 2004; Iorio et al., 2005; (Volinia et al., 2006). MiR-17–92 
cluster that comprises six miRNA genes (miR-17, miR-18a, miR-19a, miR-20a, miR-
19b-1 and miR-92a-1) and miR-155, are the first oncogenic miRNAs discovered: 
miRNAs within miR-17–92 cluster promote proliferation, inhibit apoptosis, induce 
tumor angiogenesis and cooperate with MYC to accelerate the development of 
lymphomas (Dews et al., 2006).  
Moreover, single nucleotide polymorphisms (SNPs)  (Figura 11c) occur in miRNA loci 
(affecting the sequence of mature miRNAs) or in target mRNA and can either create or 
destroy miRNA binding sites changing the their specificity to bind to and repress target 
genes (Chen and Rajewsky, 2006). The first observation was a SNP in kRAS 3’UTR 
destroying let-7 binding site and abolishing its tumor suppressor role.  
Another level of miRNA-related alterations in cancer consist of defects in the miRNA 
biogenesis machinery, such as Drosha or Dicer activity in different tumor types (Merritt 
et al., 2008). These processes include maturation from pri-mRNA to pre-mRNA, 
mediated by Drosha-DCGR8 complex, nuclear export, and cleavage by Dicer. 
Therefore, in cancer miRNAs expression is frequently decreased (Lu et al., 2005). 
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An important role in miRNA biogenesis have been described for p53. p53 is able to 
associate with DEAD-box RNA helicase p68 (DDX5) and thus interacts with the 
Drosha processing complex facilitating the processing from pri-miRNA to pre-
miRNAs. Moreover mut-p53 interferes with assembly between Drosha complex and 
p68, leading to attenuation of miRNA processing activity (Bates et al., 2005). 
A recent work shows that downstream target of the tumor-suppressive Hippo-signaling 
pathway regulates miRNA biogenesis in a cell-density-dependent manner, by 
sequestrering the Microprocessor cofactor p72 (DDX17) at low cell density. On the 
contrary, at high cell density, YAP is retained in the cytoplasm and p72 can bind the 
Microprocessor and enhance pri-miRNAs maturation. Thus, fostered activation of YAP, 
seen in cancer, may alter miRNA biogenesis (Mori et al., 2014).  
Thus the Microprocessor activity due to these two important oncogene pathways (mut-
p53 and YAP) in cancer cell may partially cause the widespread miRNA reduction 
observed in cancer. 
Moreover, in mice, a deletion of Dicer reduces total miRNAs, and mice with a single 
copy of Dicer are tumor prone. In human breast cancer samples, it has been 
demonstrated that miR-103 and miR-107 upregulation, that directly target DICER1 
mRNA, are strongly associated with metastasis (Martello et al., 2010). 
Finally, control of miRNAs transcription can also be altered in cancer. At the 
transcriptional level, cis-acting changes to the promoter, including epigenetic regulation 
(such as promoter methylation) or genomic mutations or availability of transcription 
factors may change the expression profile of miRNAs in a cell. 
In 2006, Volinia and colleagues (Volinia et al., 2006) defined a miRNA expression 
signature that distinguishes cancerous tissues from normal tissues and individuated a 
group of miRNAs whose expression is commonly altered in different solid tumors. 
These evidences suggested that these miRNAs may be downstream targets of pathways 
that are commonly dysregulated in cancer (Volinia et al., 2006). These miRNAs might 
represent excellent targets for therapeutic intervention, such as treatment with 
compounds that can inhibit their expression, including antagomirs (synthetic RNAs 
complementary to the miRNA target with modifications to inhibit their cleavage) or 
LNA (locked nucleic acid) (Bonci et al., 2008). 
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AIM OF THE STUDY 
Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) characterized 
by highly aggressive phenotype, correlated with unfavorable prognosis and lack of 
specific therapy (Choo and Nielsen, 2010). TNBC aggressiveness and metastasis are 
almost invariably observed and are indeed responsible for the majority of BC deaths 
(Reddy, 2011). At the molecular level TNBC resembles basal-like subtype of BC, 
characterized by high prevalence of p53 mutant expression (over 50% of TNBCs). 
Missense point mutations in the TP53 gene are one of the most frequent genetic events 
in human cancers and generate mutant-p53 proteins that lost wild-type tumor 
suppressive functions, and paradoxically acquired oncogenic properties (“gain-of-
function”, GOF). 
miRNAs are key regulators of gene expression frequently deregulated in cancer, with 
some of them acting as either as oncogenes or tumor suppressors.  
On this basis the specific aim of this work is to dissect the role of mut-p53 in epithelial 
cell polarity disruption through the miRNA players. In particular we wanted investigate 
whether mut-p53 oncogenic function in TNBC could induce aberrant expression or 
function of microRNAs, thus favoring the acquisition of TNBC aggressive features. The 
main parts of this work are: 
• Identify a miRNA regulated by mut-p53, performing a screening of miRNAs 
previously described to be overexpressed in BC and other solid tumors. Among 
miRNAs positively regulated by mp53 we identified miR-30d, already involved 
in tumor invasion and metastasis; 
• Investigate if the mutp53/miR-30d axis contributes to epithelial cell polarity 
disruption and cancer aggressivness; 
• Unveil the possible mechanism by which mutp53/miR-30d axis operates. 
A better understanding of the molecular basis of TNBCs and the identification of 
new molecular targets are required to develop new effective treatments against this 
aggressive BC subtype. I propose that these findings will add a novel layer of 
complexity to mut-p53 GOF regulation and will provide new mechanism to target 
with specific drugs to tackle TNBC aggressiveness. 
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RESULTS 
Selection of candidate oncogenic miRNAs controlled by mutant p53 
Mutant p53 could perturb miRNAs both positively and negatively, similarly to protein 
coding genes. Accordingly, these miRNAs could be overexpressed (in the first case) or 
downregulated in cancer. Since aim of our work is to find miRNAs which expression is 
associated with mut-p53 that could be involved in p53 gain-of-function, I decided to 
focus on this first category by searching for microRNAs reported in the literature to be 
part of different miRNAs signature in cancer, overexpressed in cancer or in cancer-
derived cell lines. 
I generated a panel of 16 selected miRNAs known to be overexpressed in BC and other 
solid tumor: miR-17-5p, miR-20a, miR-21, miR-24, miR-25,miR-29b, miR-30c, miR-
30d, miR-92, , miR-106a, miR-107, miR-128b, miR-146a, miR-181b, miR-191 and 
miR-221 (see Table 1 for a list of tumors in which they were found overexpressed).  
To verify whether mut-p53 affects the expression level of putative oncogenic miRNAs, 
I decided to evaluate the expression of these 16 selected miRNAs in MDA-MB-231 
cells upon mut-p53 depletion by RNAi. Cells were transfected with double-stranded 
small interfering RNA oligonucleotides targeting p53 (sip53) or with control siRNA 
(CTRL, Qiagen Allstar negative control), as shown in Figure 12, I identified 7 miRNAs 
(miR-20a; miR-30d; miR-181b; miR-106a; miR-107; miR-146a; miR-221) that were 
significantly downregulated by depletion of mutant p53.  
Figure 12. Screening to evaluate microRNAs regulated by mut-p53.  Bar graph showing expression of a solid 
cancer miRNAs signature by qRT-PCR in MDA-MB-231 cells. MDA-MB-231 cells were transfected with either 
p53-specific or control siRNA. 48h after transfection, the RNA was extracted and performed a q-RT-PCR.  
 (n = 3, *= p<0,001 comparing the expression of each miRNA between the indicated conditions, two-tailed t-test).  
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microRNA Accession Tumors Reference 
hsa-miR-17-5p MI000007 
Breast, colon, lung, 
pancreas, prostate 
(Volinia et al., 
2006) 
hsa-miR-20a MI0000076 
Colon, pancreas, 
prostate  (Volinia et al., 2006) 
hsa-miR-21 MI0000077 
Breast, colon, lung, 
pancreas, prostate, 
stomach, 
glioblastoma, CLL 
(Fulci et al., 2007; Hu et 
al., 2010; Iorio et al., 
2005; Kulshreshtha et 
al., 2007; Volinia et al., 
2006) 
hsa-miR-24 MI0000080 
Colon, pancreas, 
stomach  
(Kulshreshtha et al., 
2007); Volinia et al., 
2006) 
hsa-miR-25 MI0000082 
Pancreas, prostate, 
stomach  (Volinia et al., 2006) 
hsa-miR-29b  MI0000105 
Breast, colon, 
pancreas, prostate  (Volinia et al., 2006) 
hsa-miR-30c  MI0000736 
Colon, pancreas, 
prostate  
(Kulshreshtha et al., 
2007; Volinia et al., 
2006) 
hsa-miR-30d MI0000255 
Breast, Liver, 
Melanoma Ovary 
(Garzon et al., 2008); 
Hu et.al., 2010) 
hsa-miR-92 MI0000093 
Pancreas, prostate, 
stomach, CLL  
(Fulci et al., 2007; Volinia 
et al., 2006) 
hsa-miR-181b MI0000270 
Breast, pancreas, 
prostate  
(Kulshreshtha et al., 2007; 
Volinia et al., 2006) 
hsa-miR-106a  MI0000113 
Colon, pancreas, 
prostate,leukemia,ne
uroblastoma 
(Kulshreshtha et al., 2007; 
Volinia et al., 
2006;(Ambs et al., 2008) 
hsa-miR-107 MI0000114 
Colon, pancreas, 
stomach  
(Kulshreshtha et al., 2007; 
Volinia et al., 2006) 
hsa-miR-128b  MI0000727 
Colon, lung, 
pancreas (Volinia et al., 2006) 
hsa-miR-146 MI0000477 
Breast, pancreas, 
prostate  
(Volinia et al., 2006; Hu 
et.al., 2010) 
hsa-miR-191  MI0000465 
Colon, lung, 
pancreas, prostate, 
stomach, AML 
(Volinia et al., 2006) 
(Garzon et al., 2008) 
hsa-miR-221 MI0000298 
Colon, pancreas, 
stomach, prostate (Volinia et al., 2006) 
 
Table1. List of 16 microRNAs selected as candidate oncogenes. microRNAs names and accession numbers are 
indicated (http://www.mirbase.org/). Tumors or tumor derived cell lines (and relative references) in which they were 
found deregulated are reported.  
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The intergenic miRNA miR-30d is one of the five members of the miR-30 family, and it 
is localized in chromosome 8q24.22, it is probably transcribed in a cluster with its 
paralogue mir-30b. Interestingly, a prometastatic role for miR-30d has been recently 
shown in hepatocellular carcinoma (Yao et al., 2010) and melanoma (Gaziel-Sovran et 
al., 2011). Moreover, the presence of increased levels of miR-30d in the sera of patients 
with lung cancer correlates with poor prognosis (Hu et al., 2010). Altogether, these 
studies indicate that miR-30d might exert a prometastatic effect, in a similar way to 
mut-p53, thus making it a strong candidate miRNA contributing to mut-p53 GOF and 
TNBC aggressiveness, and so I selected it for further characterization. 
Mutant p53 regulates miR-30d levels 
In order to confirm the dependency of miR-30d expression on mut-p53, I selectively 
analyzed expression of miR-30d in cell lines other than MDA-MB-231, were (as shown 
in Figure 13A) mut-p53 knockdown caused a 45% reduction of miR-30d levels. Results 
were also recapitulated in other BC cell lines expressing endogenous mut-p53, such as 
MDA-MB-468 and Sk-Br-3 (Figure 13B-C respectively). Importantly, this effect was 
strictly dependent on mutant p53 expression, since in MDA-MB-231 cells depleted of 
endogenous mut-p53 transfected with double-stranded small interfering RNA 
oligonucleotides targeting the 3’UTR of p53, the ectopic re-introduction of siRNA 
insensitive p53R280K coding sequence, restores miR-30d expression (Figure 13D). 
Moreover, we generated multiple MCF-10A cell lines in which the mutants R280K, and 
R175H were expressed ectopically in cells previously depleted of wild-type p53. In this 
system, while wt-p53 knock down is not impinging on miR-30d expression, mut-p53 
overexpression induces miR-30d expression (Figure 13E)  
To investigate how mut-p53 promotes miR-30d expression, I first monitored the levels 
of pri-miR-30d primary and pre-miR-30d hairpin precursors in MDA-MB-231 cells 
depleted of mut-p53. As shown in Figure 14 mut-p53 knockdown caused a 30% 
reduction of pri-miR-30d (Figure 14A) levels and 47% of pre-miR-30d (Figure 14B).  
These results demonstrated that in breast cancer cells line, mut-p53 controls the 
expression of miR-30d, and suggested that mut-p53 could regulate miR-30d mature 
levels most likely by affecting transcription of its precursor.  
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Figure 13. mut-p53 promotes miR-30d expression in human breast cancer cells. A-B-C Bar graph showing 
expression of miR-30d in MDA-MB-231, MDA-MB-468, Sk-Br3 cells upon mut-p53 knockdown. Cells were 
transfected with either p53-specific or control siRNA and collected 48h after transfection, the RNA was extracted and 
q-RT-PCR was performed a. (n = 3, p value is reported in graph between the indicated conditions, two-tailed t-test). 
mut-p53 is required for miR-30d expression. D Bar graph showing expression of miR-30d in MDA-MB-231 cells 
transfected with either p53 3’UTR-specific or control siRNA, and transduced with p53 mutants or empty vector (-) as 
a negative control. (n = 3, p value is reported in graph between the indicated conditions, two-tailed t-test) 
E Bar graph showing expression of miR-30d in MCF10A stably silenced for wt-p53 and overexpressing mut-p53 
R280K, and R175H.  (n = 3, p value is reported in graph between the indicated conditions, two-tailed t-test). 
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Figure 14. mut-p53 promotes miR-30d expression in human breast cancer cells. Bar graph showing expression 
of pre-miR-30d and pri-miR-30d in MDA-MB-231, upon mut-p53 knockdown. Cells were transfected with either 
p53-specific or control siRNA and collected after 48h after transfection, the RNA was extracted and q-RT-PCR was 
performed (n = 3, p value is reported in graph between the indicated conditions, two-tailed t-test). 
 
miR-30d mediates mut-p53 dependent epithelial cell polarity disruption  
In a course of tumor progression, epithelial cancer cells can undergo a transition to a 
detached and disseminated cell migration. In 2011 Zhang and colleagues (Zhang et al., 
2011) identified a new mutant p53 gain of function in the alteration of cell polarity via 
EMT. In in vitro 3D cell culture models we can distinguish malignant from normal 
tissue architecture. Non-malignant 3D culture breast cells, such as immortalized breast 
cells line MCF-10A, undergo a small number of cell division rounds after which they 
organize in spheroid structures referred to as acini structures reminiscent of polarized 
mammary acini found in vivo (Debnath et al., 2003). Each acinus consists of a single 
layer of polarized luminal epithelial cells surrounding a hollow lumen. In contrast, 
malignant cell mass adopts various morphologies with common tissue polarity loss and 
disorganized architecture (Lee et al., 2007). 
To study the mutant-p53 dependent polarity disruption, I cultured in 3D Matrigel cell 
culture system the MCF10A cell line in which upon depletion of wild-type p53 the 
mutants R175H and R280K were expressed ectopically. 
Endogenous wild-type p53 is not required for acini formation; in fact p53 knockdown in 
MCF-10A lead only to a partial clearance of cells in the lumen. On the contrary, ectopic 
overexpression of siRNA-resistant mutant R175H, and R280K, disrupts normal acini 
architecture and are characterized by irregular shape and a totally filled lumen.  
To examine the role of mir-30d in mediating mutant-p53 dependent polarity disruption, 
I engineered a lentiviral GFP-miR30d decoy vector to stably inhibit miR-30d. miR-30d 
inhibited MCF-10A cells, even overexpressing ectopic mutant R175H, and R280K  are 
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characterized by a recovery of more normal mammary phenotype in 3D culture; they 
form round colonies on top of a gel that re-acquire the hollow lumen formation as 
judged by analyzing nuclei organization localization by confocal microscopy (Figure 
15A). 
Moreover, to verify the direct effect of miR-30d in epithelial cell polarity disruption, I 
generate MCF-10A cells stably overexpressing miR-30d, and they were cultured in the 
matrigel to perform 3D culture assays. 3D structures were analyzed by 
immunofluorescence using specific acinar structure markers. Clearly, as shown in 
Figure 15B, miR-30d overexpression in MCF-10A completely altered the formation of 
3D structures, inducing a “mass-like” disorganized structures; miR-30d impairs the 
formation of the hollow lumen, causing the alteration of basement membrane, as seen 
by laminin V staining. I also observed the mislocalization of ZO-1, a tight junction 
protein, for normal localization in the apical side of cells, to the baso-lateral region. 
In 3D cultures aggressive breast cancer cells form colonies with poor cell–cell contacts, 
disorganized nuclei - distinguished by a formation of grape-like or stellate structures, 
(Lee et al., 2007). The aggressive breast cancer cells line MDA-MB-231 were 
transduced with the lentiviral GFP-miR30d decoy vector or control vector. The 3D 
culture experiments with miR30d-stably inhibited MDA-MB-231 cells, showed that 
miR-30d inhibited cells are characterized by less aggressive, “mass-like” phenotype in 
respect to malignant “stellate” phenotype of control MDA-MB-231 - as viewed by 
phase contrast microscopy, and by analyzing nuclei organization and actin localization 
by confocal microscopy (Figure 15C). 
In fact, stable inhibition of miR-30d in MDA-MB-231 lead to a strong reduction of 
stellate colonies (from 38% to 12%) and a concomitant increase of mass like colonies. 
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Figure 15. miR-30d affects epithelial cell polarity:  
A Mut-p53 effect in disorganizing normal acinar structure of MCF-10A cells in a 3D culture is mediated by 
miR-30d: Representative pictures of pLPC (CTRL, control) and MCF10A stably silenced for wt-p53 and 
overexpressing mut-p53 R280K and R175H either with or without stably inhibition of miR-30d (decoy-miR-30d). 
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Images show MCF-10A cells growing in 3D cultures for 14 days obtained by fluorescence pictures showing polarity 
analysis by confocal microscopy of Laminin V (green), and nuclei (red) staining. 
B miR-30d disorganizes normal acinar structure of MCF-10A cells in a 3D culture: 
Representative pictures of pRS (CTRL, control) and stably expressing miRVec-30d  MCF10-A cells growing in 3D 
cultures for 14 days obtained by using 40X objective in a contrast phase microscopy and fluorescence pictures 
showing polarity analysis by confocal microscopy of Laminin V (green), ZO1 (blue) and nuclei (red) staining. 
C miR-30d inhibition partially restores normal structure of MDA-MB-231 cells in a 3D culture: 
Representative pictures of MDA MB-231 cells trasduced with vectors encoding the miR-30d decoy, grown in 3D 
conditions for 7 days. pictures were obtained by using 40X objective in a contrast phase microscopy and by 
fluorescence showing polarity analysis by confocal microscopy of actin (blue), and nuclei (red) staining. 
Histogram showing the specific morphological cellular 3D growth structures analyzed by confocal microscopy and 
categorized and plotted as a percentage of the total structure population. 
 
miR-30d induces EMT and Stemness feature acquisition 
An increasing number of evidences shown that the loss of polarity is strictly linked to 
epithelial to mesenchimal transition (EMT) (Zhang et al., 2011). MCF-10A breast cells 
overexpressing miR30d show a clear EMT-related morphology change.  Accordingly, I 
have investigated the impact of miR-30d on this process and in these cells I detected an 
increased expression of the mesenchimal markers Vimentin and Fibronectin, and the 
reduction of the epithelial marker E-cadherin by qRT-PCR analysis (Figure 16A), and 
of Vimentin and E-cadherin by immunofluorescence (Figure 16B) and western blot 
(Figure 16C).  
Studies on embryonic stem cells (ES) and mesenchymal cells suggest that the EMT 
process correlates with the appearance of cell populations enriched in Cancer Stem 
Cells (CSCs). In fact, cells undergoing EMT acquire stem cell-like proprieties (Mani et 
al., 2008) and indeed it was demonstrated that more aggressive tumor cell lines and 
High-grade tumors are characterized by increased number of cancer stem cells (Pece et 
al., 2010). 
I thus asked whether feature of CSCs, can be also regulated by miR-30d. With this 
purpose, I stably inhibited endogenous miR-30d in MDA-MB-231 and performed the 
mammosphere formation assay. As shown in Figure 17, miR-30d does not affect the 
generation of primary mammospheres, but in order to evaluate the self-renewal 
capability of these cells, primary mammospheres were dissociated and reseeded in order 
to form secondary mammopheres.   Interestingly, in the second generation miR-30d 
stable inhibition causes a 40% reduction respect the control ones.  
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Altogether, these results allowed us to conclude that miR-30d promotes EMT and self-
renewal of breast cancer cells, and this could contribute TNBC aggressiveness 
acquisition. 
 
Figure 16. miR-30d induces EMT transition of normal MCF-10A cells. 
A Bar graph showing expression of Fibronectin, Vimentin (as a mesenchymal marker) and E-cadherin (as a  
epithelial marker) in MCF-10A overesspressing miR-30d. the RNA was extracted and q-RT-PCR was performed  (n 
= 3, p value is reported in graph between the indicated conditions, two-tailed t-test).  
B Immunofluorescence of E-cadherin epithelial marker (red),or Vimentin as mesenchymal marker and Hoechst 
(nuclear marker, blue) MCF-10A cells upon miR-30d stable overexpression (nuclear marker);  Images were obtained 
by using 100X objective with Leica DM4000B epifluorescence microscope. 
C MCF-10A cells upon miR-30d stable overexpression and western blot detection of E-cadherin, Vimentin and 
HSP90 as loading control;  
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Figure 17. miR-30d is required to sustain the cancer stem cell population. 
Quantification of primary M1 and secondary M2 mammospheres generation of MDA-MB-231 stably inhibited for 
miR-30d and/or Control. (n = 3, p value is reported in graph between the indicated conditions, two-tailed t-test).  
 
 
miR-30d contributes to mut-p53 oncogenic (GOF) properties. 
In addition, EMT confers to cancer cells the mesenchymal state associated with the 
capability of cells to migrate to distant organs and develop metastasis. 
To assess the contribution of miR-30d to cell migration, I first analyzed that miR-30d 
effect on cell migration. I demonstrated that miR-30d induces cell migration in cell lines 
in a p53 null contest: indeed overexpression miR-30d causes an increase (150% respect 
to the control) of migration of H1299 cells (a model of human non-small cell lung 
carcinoma p53null) upon miR-30d over-expression (Figure 18A). On the contrary, 
blocking endogenous miR-30d by mean of a specific inhibitor causes a significant 
reduction of cell migration (67% compared to the control) of MDA–MB-231 cells 
(Figure 18B).  
To establish whether miR-30d could mediate mut-p53 oncogenic function in human 
cancer cells, I investigated miR-30d contribution to mut-p53-dependent cell migration 
and invasion. In particular I verified that over-expression of miR-30d rescues the 
phenotype caused by mut-p53 depletion in MDA–MB-231 cells: as shown in Figure 
19A-B there is a significant reduction of migration (57% compared to the control) and 
invasion (45% respect the control) upon mut-p53 silencing, while over-expression of 
miR-30d in these cells rescues migration (89% compared to the control) and invasion 
(96% compared to the control) capability of these cells. 
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Figure 18. miR-30d promotes cell migration. A Transwell migration assays of H1299 cells transfected with either 
miR-30d or control; bar graph showing percentage of migrated cells (Error bars indicate s.d. n = 3, p value is reported 
in graph between the indicated conditions, two-tailed t-test) . In the bottom panel a representative picture of  migrated 
cells is reported. 
miR-30d inhibition reduces cell migration. B Transwell migration assays of MDA-MB-231 cells transfected  with 
miR-30d inhibitor or control;bar graph showing percentage of migrated cells (Error bars indicate s.d. n = 3, p value is 
reported in graph between the indicated conditions, two-tailed t-test). . In the bottom panel a representative picture of  
migrated cells is reported. 
 
 
Moreover, since the capability to increase the cells’ growth and replication rate is 
another critical aspects of mut-p53 oncogenic phenotype, I evaluated whether miR-30d 
could play a role also in this process. In MDA-MB-231 cells there is a significant 
reduction of proliferation (34% compared to the control at 72h) upon mut-p53 silencing, 
while over-expression of miR-30d in these cells partially restores the proliferation (60% 
compared to the control) of these cells (Figure 19C). 
All together these data demonstrate that miR-30d is able to exert mut-p53 migratory, 
invasive and proliferative GOF. 
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Figure 19. miR-30d mediates mp53 GOF 
miR-30d mediates mut-p53 dependent cell migration. A Transwell migration assays of MDA-MB-231 cells, 
transfected twice with either p53-specific or control siRNA and, during second transfection, vector over-expressing 
miR-30d or control vectorbar graph showing percentage of migrated cells (Error bars indicate s.d. n = 3, p value is 
reported in graph between the indicated conditions, two-tailed t-test); . In the bottom panel a representative picture of  
migrated cells is reported. 
miR-30d mediates mut-p53 dependent cell invasion. B Transwell invasion assays of MDA-MB-231 cells, 
transfected twice with either p53-specific or control siRNA and during second transfection, vector over-expressing 
miR-30d or control vector; bar graph showing percentage of invading cells (Error bars indicate s.d. n = 3, p value is 
reported in graph between the indicated conditions, two-tailed t-test). . In the bottom panel a representative picture of 
invasive cells is reported. 
miR-30d mediates mut-p53 dependent cell proliferation. C MDA-MB-231 cells, transfected twice with either 
p53-specific or control siRNA and during second transfection it was over-expressed miR-30d or control, 48h after the 
second transfection cells was plated and than counted at 24-48-72h. (Error bars indicate s.d. n = 3) 
mut-p53 regulates the expression of DLG5 and TIMP3 through miR-30d 
In order to identify target responsible mut-p53/miR-30d phenotypes, I looked for 
putative miR-30d targets regulated by mut-p53/miR-30d axis. 
Having demonstrated that miR-30d expression is positively regulated by mut-p53, the 
levels miR-30d direct targets should be inversely correlated with mut-p53 expression. 
According to this hypothesis, I looked for putative miR-30d target by taking advantage 
of the TargetScan program (www.targetscan.org) that is one of the most accurate and 
reliable among available algorithms of miRNA target identification (Baek et al., 2008; 
Selbach et al., 2008), identifying 1357 different transcripts. Then I checked if direct 
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these miR-30d predicted target are present in the transcriptional profile of mut-p53-
depleted MDA-MB-231 cells, already available in our lab (Girardini et al., 2011). In 
particular I considered only those genes (250) whose expression is increased at least of 
2 fold upon mut-p53 depletion. By matching these 2 gene sets I obtained a list of 33 
common genes (Figure 20A), representing putative novel candidate genes modulated by 
mut-p53 through miR-30d.  
Among them I selected a small group of 8 genes (Figure 20A) following two criteria: 
(1) containing of a perfect and conserved seed match sequence for miR-30d or (2) 
containing of two miR-30d binding sites close to each other (10-40 nt apart).  
To confirm if the expression of these predicted target genes is affected by mut-p53/miR-
30d axis, I analyzed the endogenous level of candidate mRNA after ectopically 
expression miR-30d in mut-p53 knocked-down cells. As hypothesized, I observed that 
TIMP3, DLG5, PLXNA1, ADAM19, LPHN3 mRNA levels increased upon mut-p53 
deletion, but this is not observed when miR-30d is further over-expressed in this context 
(Figure 20B).  
Based on these results, a series of constructs containing the 3’UTR of TIMP3, DLG5, 
PLXNA1, ADAM19, LPHN3 were generated by cloning them downstream the 
luciferase cDNA. 
These reporter constructs were transfected in H1299 cells together with miR-30d mimic 
or control. As reported in figure miR-30d overexpression caused a slight but significant 
decrease of the luciferase activity in only 3’UTR of TIMP3, DLG5 and ADAM19 
(Figure 20C).  
Moreover, I next tested the action of miR-30d in 3’UTR of TIMP3, DLG5 and 
ADAM19 by co-transfecting them with the miR-30d inhibitor hairpin or control, and 
only for 3’UTR of DLG5, TIMP3 we can observed a slight increase of the luciferase 
activity, thus confirming that DLG5 and TIMP3 are a direct targets of miR-30d (Figure 
20C). 
In line with these observations, I demonstrated that blocking endogenous miR-30d with 
specific inhibitor in MDA–MB-231 cells causes a strong increase of TIMP3 and DLG5 
protein levels (Figure 20D).  In addition, DLG5 and TIMP3 proteins levels increased 
upon mut-p53 depletion in accordance with the effects on mRNA and this effect is 
reverted when miR-30d is over-expressed in this condition (Figure 20D).  
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Figure 20. Analysis of miR-30d predicted targets and their validation.  
A: Identification of miR-30d predicted targets. Venn diagram showing the overlap between predicted target genes 
of miR-30d by TargetScan and genes up-regulated (>2 fold) upon mutant p53 silencing in MDA-MB-231 cells. 
Listed in the table, in red are indicated genes whith a perfect match of the seed sequence for miR-30d, and sites are 
conserved. 
B: Validation of mut-p53/miR-30d targets. MDA-MB-231 cells, transfected twice with either p53-specific or 
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control siRNA and during second transfection it was over-expressed miR-30d or control. 48h after the second 
transfection, the RNA was extracted and gene expression was evaluated by q-RT-PCR. (n = 4, * = p<0,05, two-tailed 
t-test). 
C: H1299 cells were  transfected with 1000 ng of PG13-luc reporter construct and 250 ng of CMV-renilla construct 
for normalization of transfection efficiency. After 24h 6*104 cells were seeded in 24-well plates and transfected with 
mimic-miR-30d or inhibitor-miR-30d and a relative control. Luciferase activity was measured after 18 hours. Data 
represent the mean and s.d. of three independent experiments. p‑values are relative to control. 
D: Timp3 and DLG5 are targets of the mut-p53/miR-30d axis. MDA-MB-231 cells treated as in B, cells were 
lysed and proteins were analyzed through Western Blot using specific antibodies for TIMP3 (Abcam) and DLG5 
(Sigma), p53 (DO-1) and HSP90.  
 
Inhibition of DLG5 mediates miR-30d oncogenic activities 
Among these targets, DLG5 is a member of the MAGUKs  family, that act as molecular 
scaffolds for signal transduction complexes, colocalizing with and binding to β-catenin 
and vinexin in adherens junction complexes (Wakabayashi et al., 2003), regulating 
delivery of cadherin-catenin adhesion complexes (Nechiporuk et al., 2007) to plasma 
membranes. Recently it has been demonstrated that DLG5 is a regulator of polarity in 
lung morphogenesis by maintaining aPKC in the apical zone (Nechiporuk et al., 2013). 
Moreover, it has been shown that loss of DLG5 may have a role in breast cancer, since 
DLG5 down-regulation was highly correlated with increasing tumor grade in four 
independent breast cancer data sets (Chin et al., 2006; Miller et al., 2005; Neve et al., 
2006; Sotiriou et al., 2006). The lowest levels of DLG5 expression were observed in 
basal-type and metaplastic (Hennessy et al., 2009) cancers, which are associated with 
EMT (Sarrio et al., 2008), stem-like characteristics, and a poor prognosis (Smolen et al., 
2010). 
To establish whether DLG5 is involved in miR-30d oncogenic activities, I investigated 
DLG5 contribution to mut-p53/miR-30d in cell migration. In MDA-MB-231 stably 
miR-30d inhibited cells we can observe a strong increase of DLG5 protein. In this 
cellular context, I verified that stable inhibition of miR-30d causes a significant 
reduction of migration capability of the cells (61% respect the control) (Figure 21A). 
The concomitant depletion of DLG-5 by three different siRNA rescues the migration 
capability of these cells. 
In summary, I identified some of miR-30d/mut-p53 target genes, and among them I 
identified DLG5 as a relevant mediator of miR-30d-dependent migration capability. 
According to the known function of DLG5, I propose that miR-30d may disrupt breast 
epithelial polarity and trigger cell transformation by targeting DLG5. I verified that 
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stable inhibition of miR-30d in MDA-MB-231 lead to a strong reduction of stellate 
colonies and an increase of mass like colonies (Figure 21B). The concomitant depletion 
of DLG-5 by a siRNA targeting its 3’UTR, rescues the 3D phenotype of these cells and 
leads to the appearance of stellate colonies also in miR-30d inhibited cells (Figure 21B). 
 
 
 
 
Figure 21. targeting of DLG5 mediates miR-30d dependent oncogenic function 
Targeting of DLG5 mediates miR-30d dependent migration. A Transwell migration assays of MDA-MB-231 
cells stably expressing miR-30d decoy, transfected with either DLG-5 or control siRNA; bar graph showing 
percentage of migrated cells (Error bars indicate s.d. n = 3, p value is reported in graph between the indicated 
conditions, two-tailed t-test); . In the bottom panel a representative picture of  migrated cells is reported. 
Targeting of DLG5 mediates miR-30d dependent ephitelial cell polarity disruption. B Representative pictures of 
MDA-MB-231 cells trasduced with vectors encoding the miR-30d decoy and transfected with either DLG-5 or 
control siRNA  grown under 3D conditions for 7 days. Pictures were obtained by fluorescencent staining, showing 
polarity analysis by confocal microscopy of actin (blue), and nuclei (red) staining. 
 
DLG5 expression is deregulated in breast cancers and its downregulation is 
correlated with poor prognosis  
To further explore the potential role of DLG5 in breast cancer, I performed a   
bioinformatic analysis of DLG5 mRNA expression by using the public available 
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datasets. I have examined the relationship of DLG5 RNA expression levels and other 
predictors commonly used in clinical practice, such as breast cancer subtypes and tumor 
grade, in different breast cancer datasets. Analysis in those datasets indicated that DLG5 
is down-regulated in the high tumor grade and lower levels of DLG5 expression were 
observed in the Basal subtypes (Figures 22, panels A and B respectively) that are 
mostly Triple Negative and frequently display TP53 mutations. 
Moreover, I wanted to check the correlation with mut-p53 and DLG5 in expression 
profiles of primary breast tumors. To this end I used a publicly available dataset (Miller 
et al. 2005) where the p53 status is reported. As shown in figure 22C, I have identified 
that DLG5 down-regulation was correlated with the presence of missense mutations on 
TP53 gene. 
All together these results clearly support the relevance of the mut-p53/miR-30d axis in 
breast cancer prognosis, since DLG5 downregulation correlates both with missense 
mutations in the TP53 gene and aggressiveness in breast cancer, and according to my 
data the DLG5 downregulation could be accomplished by miR-30d.   
 
 
Figure 22.  
A Box plot showing DLG5 expression levels as function of their tumor grade; 
B Box plot showing DLG5 expression levels in different breast cancer subtypes;  
C Miller dataset analysis of DLG5 expression in tumoral tissues with wild type (-) and mutant p53 (+) (p-
value= 0.00138).
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DISCUSSION  
Increasing knowledge about the mechanism that regulates the establishment and 
maintenance of cell polarity, have reveled its important contributions in preventing the 
tumorigenic feature acquisition.  It is still challenging to understand how cancer genes 
and pathway influence epithelial architecture (Martin-Belmonte and Perez-Moreno, 
2011). Studies in aggressive breast cancer-derived cells underscored a central role of 
mut-p53 in cell-polarity disruption (Freed-Pastor et al., 2012) and inducing EMT 
(Zhang et al., 2011). 
Despite the growing understanding of mut-p53 functions there is much left to learn. 
Little is known about miRNAs associated with mut-p53 oncogenic functions. Here I 
show that mut-p53 causes EMT, blunting the expression of DLG5 through the induction 
of miR-30d, inducing epithelial cell polarity disruption and causing cancer aggressive 
phenotypes. 
Although the widespread reduction of miRNAs expression in different cancers, some 
miRNAs with oncogenic role are up-regulated in some cancer. Despite the expanding 
list of mutant p53-regulated genes, only few miRNAs have been identified, indirectly, 
downstream to mut-p53. Thus I asked if mut-p53 could directly regulate some miRNAs 
able to mediate its gain of function. Data in literature showed that mut-p53 by inhibiting 
p63 or wt-p53 can regulate miR-155 (Neilsen et al., 2013) and miR-130b (Dong et al., 
2013) respectively, contributing to more invasive phenotypes in endometrial and breast 
cancer. A very recent work demonstrate also that mutant p53 indirectly exerts its 
oncogenic functions in breast cancer, by downregulating on of the most known 
oncosupressive miRNA, let-7i through p63 inhibition (Subramanian et al., 2014). 
Moreover, in lung cancer mut-p53 confer resistance to chemotherapeutic agents 
controlling miR-128-2 by regulating the expression of the host gene ARPP21. 
In order to identify miRNAs involved in mut-p53 oncogenic activities I analyzed the 
impact in a panel of 16 selected miRNAs known to be overexpressed in BC and other 
solid tumors and among them I identified and selected miR-30d. 
This small non coding RNA belongs to the miR-30 family that in human consists of 5 
members, hsa-miR-30a, -b, -c, -d and -e, involved in various biological and 
physiological processes. In general, although miRNAs of the same family share the 
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same seed sequence, the spectrum of regulated messenger and the effect could be 
different. This effect, that is mainly due to supplementary pairing between the mRNA 
3’UTR and the miRNAs, is observed in the miR-30 family. Indeed, in this family while 
miR-30a, -c, -e seem to exert an oncosupressive role, several reports underlay the 
oncogenic role of miR-30b/d. miR-30a suppresses the migration and invasiveness 
phenotypes of breast and colorectal cancer cell lines (Zhang et al., 2013; Zhong et al., 
2013), and miR-30e in breast cancer inhibits self-renewal capacity tumorigenesis and 
metastasis by reducing Ubc9, and induces apoptosis (Wu et al., 2009). 
Conversely, regarding the oncogenic role of miR-30b/d, particularly in melanoma, by 
targeting of GALNT7 miR30b/d is able to promote both in vitro and in vivo metastasis 
and immunosuppression (Gaziel-Sovran et al., 2011). These two miRNAs probably 
form a cluster in the 8q24 chromosome, and their loci have been found amplified in a 
wide range of tumors, including melanoma (Gaziel-Sovran et al., 2011), 
medulloblastoma (Lu et al., 2009), breast and ovarian cancer (Li et al., 2012).  
In addition, an array based Comparative Genomic Hybridization (aCGH) analysis 
shows that amplification of miR-30d locus correlates with worst ovarian cancer 
prognosis and sustained resistance to apoptosis (Li et al., 2012). 
Although the mechanism is still under investigation preliminary results suggest that 
probably mut-p53 is inducing miR-30d expression at transcriptional levels, since both 
pre- and pri-miR-30d appear to be regulated.   
My results clearly show in normal mammary epithelial cells that ectopic expression of 
mut-p53 is able to trigger the EMT trans-differentiation program by activating miR-30d. 
Therefore, it is conceivable to hypothesize that mut-p53 could represents an alternative 
mechanism to gene amplification of miR-30d to deregulate its expression in cancer. 
The critical role of miR-30d, downstream to mut-p53, in promoting tumor 
aggressiveness is underlined by its effect on normal architecture disruption that 
correlates with the acquisition of mesenchymal traits with pro-invasive features. EMT 
transdifferentiation program also includes the loss of cell-cell adhesion, the loss of cell 
polarity, and the acquisition of migratory and invasive properties (Polyak and 
Weinberg, 2009). Moreover, recent evidences show that cells that undergo EMT acquire 
also stem cell-like properties (Dontu and Wicha, 2005). 
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My results show that miR-30d contributes to sustain the cancer stem-cell pool. 
Altogether, these evidences support the notion that that miR-30d prepresents a key 
regulator of cancer aggressiveness phenotypes and acts as a critical effector of the pro-
oncogenic function of mutant p53.  
In order to identify the critical substrate of mir-30d, I performed a gene ontology 
analysis (http://david.abcc.ncifcrf.gov/) of all predicted targets of mir-30d, and found 
that a large number of them are enriched for cell junction, regulation of actin 
cytoskeleton, axon guidance, and endocytosis, all process related on maintenance of 
epithelia polarity. However I concentrated my attention only on those genes predicted to 
be target of miR-30d and whose expression inversely correlated with mut-p53 (with 
fold >2) and found among them DLG5. 
DLG5 is a PDZ-containing (PSD-95, Dlg, ZO-1) MAGUK protein (Funke et al., 2005), 
and even though it shares many structural features with the DLG family proteins, it 
contains a unique N terminus carrying a coiled-coil, a domain of unknown function 
(DUFF), and a Caspase activation and recruitment domains (CARD) domain 
(Nechiporuk et al., 2007). Similar to other DLGs, DLG5 facilitates membrane protein 
targeting, and it is required for the maintenance of AJs, regulating the delivery and 
stabilization of cadherin-catenin adhesion complex at the plasma membrane and thus 
epithelial cell polarity in mammalian brain and kidneys (Nechiporuk et al., 2007). 
Moreover, more recently the same group, analyzing the localization of various apical–
basal polarity proteins, demonstrates that DLG5 is essential for correct aPKC 
localization in lung epithelium (Nechiporuk et al., 2013). 
In line with these evidences my data support the role of DLG5 in maintenance of breast 
epithelial polarity. The mut-p53/miR-30d axis by dampening DLG5 levels can trigger 
cell polarity disruption and promote aggressive behavior of breast cancer cells. This 
data are supported by the evidence that DLG5 is down-regulated in high tumor grade, 
and lower levels of DLG5 expression were observed in breast cancers harboring 
missense mutation on tp53 gene.  
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CONCLUSION AND PERSPERCTIVES 
 
With the work presented in this thesis, I have highlighted a new mechanism that could 
mediate the acquisition of pro-metastatic phenotype, exerted by mut-p53 trough miR-
30d regulation, and partially mediated by DLG5.  
Moreover, taking into account the role of miR-30d is mediating some of mut-p53 
oncogenic phenotypes could represent a new possibility to tackle tumors. It should be 
interesting to set up a strategy based on the use of antagomir directed against miR-30d, 
in order to downregulate its expression in cells that present high levels of this 
microRNA and to investigate whether the mut-p53 oncogenic activities are impaired 
upon antagomir treatment. In this regard, the potential in vivo use of this antagomir 
could represent a new therapeutic approach.  
My data also support the notion that miR-30d could play a critical role critical in 
controlling tumor development also independently of mutant p53. In this respect 
understanding the impact of other relevant targets of miR-30d is mandatory to study 
how deregulated expression of this miRNA subverts cellular processes in normal cells.  
Also the clinical significance of the aberrant expression of  miR-30d or the clinical 
impact of its interplay with mutant p53 should be investigated. Several reports 
demonstrate that cells secrete miRNAs, both free or in exosomes in serum and saliva 
and their analysis represent a great potential to predict overall survival. Among 
miRNAs, a genome-wide serum miRNA expression profiling identified miR-30d 
significantly associated with overall survival of lung cancer patients. Therefore it will 
be of interest to see if miR-30d is secreted and if it could it act as new diagnostic 
/prognostic biomarker for Breast Cancer. 
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MATERIALS AND METHODS 
Cell culture, constructs and drug treatments. 
Cell culture: MDA-MB-231, MDA-MB-468, Sk-Br3, human embryonic kidney 
epithelial cells HEK 293T and 293GP packaging cells have been maintained in culture 
in Dulbecco’s modified Eagle’s Medium (DMEM) supplemented with 10% FBS (fetal 
bovine serum), penicillin (100 IU/ml) and streptomycin (100 IU/ml). H1299, a non-
small cell lung cancer cell line, maintained in culture in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum (FBS), 
penicillin (100 IU/ml) and streptomycin (100 IU/ml). MCF10-A, a normal mammary 
cell line, maintained in culture in DMEM/F12 medium supplemented with 5% HS 
(horse serum), penicillin (100 IU/ml) and streptomycin (100 IU/ml) plus add of growth 
factor 10 µg/ml Insulin, 0.5 µg/ml Hydrocortisone and 20 µg/ml Epidermal Growth 
Factor (EGF). All cells were maintained at 37°C in 5% CO2.  
Transfection, retroviral and lentiviral transduction. 
Cells were plated one-day before the transfection experiment. The appropriate plating 
density will depend on the growth rate and the condition of the cells. Cells that are 
50–80% confluency were used on the day of the experiment. 
Transfection: for DNA transfection Lipofectamine 2000 (Invitrogen) was used; For 
siRNA/miRNA transfections, cells were transfected with 40 nM siRNA 
oligonucleotides or 10 nM miRNAs using Lipofectamine RNAiMax (Invitrogen),  
following manufacturer’s instructions. 
siRNAs and miRNAs used in this work are listed in the following table: 
siRNA Sequence Purchase from/ Reference 
Control siRNA 
(SiQ) 
Unknown All star negative control 
(1027281,Qiagen) 
sip53 ORF GACUCCAGUGGUAAUCUAC Eurofins MWG 
sip53 3’UTR GGUGAACCUUAGUACCUAA Eurofins MWG 
siDLG5 3’UTR GGAAGGUGACUUUGGCAU Eurofins MWG 
miR-30d 
mature miRNA 
UGUAAACAUCCCCGACUGGAAG 
 
 
Pre-miR™ miRNA 
Precursors hsa-miR-30d - 
PM10756 
 
miR-Negative 
Control #1 
(CTRL) 
Unknown Pre-miR™ miRNA 
Precursor Molecules— 
Negative Control #1 
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(AM17110, Ambion) 
miR-30d 
inhibitor 
(IH30d) 
Unknown miRIDIAN Hairpin 
Inhibitor hsa-miR-30d  
 
IN-001005-01-
05 (IHC) 
Unknown miRIDIAN microRNA 
Hairpin Inhibitor 
Negative Control #1 
 
 
HEK293T or 293GP were transfected using calcium-phospate. 
Retrovirous transduction 
For retrovirus production, low confluency (∼20%) 293GP packaging cells, stably 
expressing retroviral gag and pol proteins, were transfected by 
calcium-phosphate precipitation. Briefly, cells were plated the day before the 
transfection in 10 cm2 dishes in exactly 10 ml of medium. Each different virus was 
produced by co-transfection of 10 µg of the vector of interest and 5 µg of pEnv 
encoding vector. After 8 hours, medium was changed with 10 ml of medium and 
cellsincubated at 32°C. After 48-72h the virus-containing medium was filtered (0,45 µm 
filter) and supplemented with 10% FCS and 8ug/ml polybrene. The culture medium of 
target cells growing at low confluence (∼30-40%) was replaced by the appropriate viral 
supernatant and incubated at 32°C for 24h. Each different virus was produced by 
cotransfection of 10 µg of each miR-vector (or pRS vector) and5 µg of pEnv-encoding 
vector. Infected cell populations were selected using 10 µM Blasticidin (#15205 
Sigma).  
MCF-10A non-transformed mammary epithelial cells, stably silenced for endogenous 
wt p53 (shp53), were infected with retroviruses expressing shRNA-resistant (*) p53 
mutants. 
pMSCVp53R175H, -p53R280K were obtained by cloning respectively p53R175H, and 
p53R280K coding region into pMSCV empty vector, after having introduced silent 
mutations in the region targeted by p53 siRNA by site directed mutagenesis in pLPC-
p53R175H, -p53R280K respectively. 
Infected cell populations were selected using Puromycin and Blasticidin, 2µg/ml each) 
for at least one week. 
Lentivirus transduction to stably inhibits miR-30d Lentivirus were been made by 
transient transfection of 
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HEK-293T cells with the packaging plasmids and with TWEEN 3’UTR decoy 30d or 
TWEEN 3’UTR empty, using standard calcium-phosphate method. After 48 h 
incubation at 32°C, the supernatants containing viral particles were the virus-containing 
medium was filtered (0,45 µm filter), supplemented with 10% FCS and 8ug/ml 
polybrene and medium to cells for 24 h and then washed. . Infected cell populations 
were selected using Puromycin 2µg/ml. 
Constructs: pRSshp53 were previously described in pRS-shp53 and pRS vectors were 
kindly provided by R.Agami. Luciferase reporters PG13luc, and CMV renilla 
normalization construct were previously described (Mantovani et al., 2004; Mantovani 
et al., 2007). miR-Vec constructs were part of the miR-Lib, provided in collaboration by 
R. Agami (Voorhoeve et al., 2006). The 3’UTRs sequences of DLG5, ADAM19, 
TIMP3, PLXNA1 and LPHN3 were obtained from Ensembl 
(http://www.ensembl.org/index.html) and UCSC (http://genome.ucsc.edu/cgibin/ 
hgGateway) databases. pGL3 3’UTR reporters were obtained by cloning each 3’UTR 
into the pGL3-Spacer vector (derived from PGL3-Control vector), kindly provided by 
R. Agami. 3’UTRs were amplified from MDA-MB-231 genomic DNA with 
AccuPrime™ Taq DNA Polymerase High Fidelity Invitrogen), following 
manufacturer’s instructions. 
The TWEEN 3’UTR EGFP empty was kindly provided by R. De Maria, and the miR-
30d decoy was cloned as described by (Bonci et al., 2008) 
List of oligonucleotides used in this thesis. All oligonucleotides were purchased from 
MWG Biotech. 
Use  Name Sequence 
Cloning DLG5 3’UTR 
in pGL3-spacer vector 
DLG5 3'UTR 
FW 
5’ cat cat cat atg GAG AAT GCT GTG CTG TGG AT -
3’UTR 
DLG5 3'UTR 
REV 5'-cat cat acc ggt CCC AGT CTG TCA GCT CAG TA -3' 
Cloning ADAM19 
3’UTR in pGL3-spacer 
vector 
ADAM19 
3'UTR FW 5’ cat cat gac gtc ACC TGT CCA AGG GGC TTC -3’  
ADAM19 
3'UTR REV 
5'-cat cat acc ggt TAA CAT TGC AAA TGA CAA ACA 
ATT C - 3' 
Cloning TIMP3 3’UTR 
in pGL3-spacer vector 
TIMP3 
3'UTR FW 5’ cat cat gac gtc ACC TCA CTT CCC TCC CTT -3’UTR 
TIMP3 
3'UTR REV 
5'-cat cat acc ggt GAA CAT TAT GCA ACA TTA CAA 
GAC -3' 
Cloning PLXNA1 
3’UTR in pGL3-spacer 
vector 
PLXNA1 
3'UTR FW 5’ cat cat gac gtc GCC CCA GCT GTG ATC ATC -3’UTR 
PLXNA1 
3'UTR REV 
5'-cat cat acc ggt GTT TAA TCT CTC CTT AAT GTG 
TGT G -3' 
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Cloning LPHN3 
3’UTR in pGL3-spacer 
vector 
LPHN3 
3'UTR FW 
5’ cat cat gac gtc AAG ATG ACA CAG AAA TTG GAA 
CCA A -3’  
LPHN3 
3'UTR REV 
5'-cat cat acc ggt CTC AAT CAG TTG TTT ATT GGT 
TGG C - 3' 
Cloning miR-30d 
decoy in TWEEN 
3’UTR EGFP 
dy30d UP 
5´-TCGAG CTT CCA GTC GGG GAT GTT TAC A 
AGAGAACTTAGAGAACTT CTT CCA GTC GGG GAT 
GTT TAC A T-3´ 
dy30d 
DOWN 
5´-CTAGA TGT AAA CAT CCC CGA CTG GAA G 
AAGTTCTCTAAGTTCTCT TGT AAA CAT CCC CGA 
CTG GAA G C-3´ 
 Fibronectin qPCR 
 Fibronectin   
FW 5'- CAGTGGGAGACCTCGAGAAG-3' 
 Fibronectin   
REV 5'-TCCCTCGGAACATCAGAAAC-3' 
Vimentin qPCR 
Vimentin   
FW 5'- GAGAACTTTGCCGTTGAAGC-3' 
Vimentin   
REV 5'-GCTTCCTGTAGGTGGCAATC-3' 
E-cadherin qPCR 
E-cadherin   
FW 5'-TGCCCAGAAAATGAAAAAGG-3' 
E-cadherin   
REV 5'-GTGTATGTGGCAATGCGTTC-3' 
DLG5 qPCR 
DLG5   FW 5'-CGGCCGAAGCTTGCTCCAG – 3’ 
DLG5   REV  5’ – TCCGGGGAACAGTGCCCACA – 3’ 
ADAM19 qPCR  
ADAM19   
FW  5´- CCTCTGGCAGCACTTGCCCC-3' 
ADAM19   
REV 5´- AGCTCAGAGGCGGCCAGACA-3´ 
TIMP3 qPCR  
TIMP3   FW 5’- CAGCTGGAGCCTGGGGGACT -3’ 
TIMP3   REV 5’- TGCCGAAGGGCCCCTCCTTT -3’ 
PLXNA1 qPCR  
PLXNA1   
FW  5´-ACCAGTCCTGCCTGTCCTGTGT -3´ 
PLXNA1   
REV 5'-TGCGTGGAGGGCAGGATCTGT-3´ 
LPHN3 qPCR  
LPHN3   FW 5'-GGCTCACAGAGCCGAATCCGTA -3´ 
LPHN3   
REV 5'-TCGCCGCTGGCAATGCTGTAA-3´ 
MAN1A2 qPCR 
MAN1A2   
FW 5'-GGGAAGCAGCACTGGCCATTGAAA -3´ 
MAN1A2   
REV 5´- AGGTCATCACCGGAGAACAGCA -3´ 
PFN2 qPCR 
PFN2   FW 5'-GCTGTCGGCAGAGCTGGTAGA-3´ 
PFN2   REV 5'-TGGGGAGAGGCTGCTTACACA-3´ 
DPYSL2 qPCR 
DPYSL2   
FW 5'-CGGAAGGTGGAGATCCGGAGGG-3´ 
DPYSL2   
REV 5'-TGGTCTTCACTCCTCCTGGCACA -3´ 
H3 
H3 RW 5’ - GTGAAGAAACCTCATCGTTACAGGCCTGGT - 3’ 
H3 REV 5’ - CTGCAAAGCACCAATAGCTGCACTCTGGAA - 3’ 
 
Western blot analysis and antibodies.  
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Total cell extracts were prepared in Lysis buffer (50 mM Tris-HCl pH 7,5, 300 mM 
NaCl, 1% NP40, 1 mM EDTA) supplemented with 1 mM PMSF, 5 mM NaF, 1 mM 
Na3VO4, 10µg/ml CLAP, 1µM TSA and 5µM nicotinamide. Protein concentration was 
determined with Bio-Rad Protein Assay Reagent (#500-0006, Bio-Rad). Western blot 
analysis was performed according to standard procedures using the following primary 
antibodies: 
Target  Antibody  Usage 
HSP90  sc-13119 (Santa Cruz)  1:5000 1h RT 
p53 (DO1)  sc-126 (Santa Cruz)  1:1000 1h RT 
Actin #A9718 (Sigma)  1:2000 1h RT 
DLG5  #HPA000555 (Sigma) 1:1000 ON 
TIMP3 ab61316 (Abcam) 1:2000 ON 
E-cadhrin  #610182 (BD Transduction) 1:1000 1h RT 
Vimentin  ab8069 (Abcam) 1:1000 ON 
 
RNA extraction and qPCR.  
Total RNA was extracted with QIAzol lysis reagent (Qiagen) following manufacturer’s 
instructions. 1µg of total RNA was retrotranscribed with miScript PCR System 
(Qiagen). miR-17-5p, miR-20a, miR-21, miR-24, miR-25,miR-29b, miR-30c, miR-30d, 
miR-92, , miR-106a, miR-107, miR-128b, miR-146a, miR-181b, miR-191 and miR-221 
and the housekeeping gene control U6B and SNORD25 small nuclear RNA, were 
amplified with miScript PCR System (Qiagen), following manufacturer’s instructions.  
Fibronectin, Vimentin, E-cadherin, DLG5, ADAM19, TIMP3, PLXNA1, LPHN3, 
MAN1A2, PFN2, DPYSL2 and the housekeeping gene control H3 were amplified with 
SSOADV Sybr green SMX  (Biorad) following manufacturer’s instructions. A CFX96 
Touch™ Real-Time PCR Detection System (Biorad) was used for qPCRs. 
 
3D (three-dimensional) cell cultures morphology assay. 
For 3D cell culture morphology assay single cell suspensions derived from monolayer 
cultures were plated at a density of 1500 cells/cm2 for MDA-MB-231 and 5000 
cells/cm2 for MCF10-A on EHS (Engelbreth-Holm-Swarm extracellular matrix extract) 
growth factor-reduced (Matrigel, BD Biosciences) and cells were seeded in assay 
DMEM F-12 medium containing 2% EHS-Matrigel, DMEM F-12 medium 2% HS and 
supplemented with 10 ug/ml insulin, 0.5ug/ml hydrocortisone (Sigma) and 5 ng/ml EGF 
only for MCF10-A cultures. Cells were refed with Assay Medium containing 2% 
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Matrigel every 4 days. For MDA-MB-231 the cell morphology were observed and 
counted using a 4x objective on a phase contrast microscope. For MCF10-A 3D the 
morphology was observed by immunostaining and confocal microscopy of laminV, β-
catenin and HOEST nucleus staining. Cells were fixed using 4% formaldehyde at room 
temperature for at least 30 min. Then, the cells were permeabilized for 10 min at 4°C 
with 1% Triton X-100 and subsequently blocked for 
1 hr at room temperature with PBS containing 0.1% Tween-20, 0.1% BSA and 10% 
FBS. Primary antibodies were incubated with the cultures over night at 4°C, followed 
by three washes, and addition of fluorescently-conjugated secondary antibodies for 1h 
at room temperature. Nuclei were counterstained with Propidium Iodide (Sigma 
#P4170). Morphological categories as indicated were determined and plotted as a 
percentage on 200 cells observed.  
 
Immunofluorescence.  
Cells were seeded on coverslips in 6-well plates for 24 h. The cells were washed with 
PBS (phosphate-buffered saline) and fixed with 3% paraformaldehyde for 20 min. The 
fixed cells were washed twice with PBS and permeabilized with 0.1% Triton X-100 at 
room temperature for 5 min. The primary antibody was diluted in FBS (3% (v/v) fetal 
bovine serum, 2% (w/v) bovine serum albumin in PBS), and each coverslip was 
incubated with diluted antibody for 1 h at room temperature or over night 4°C. The 
coverslip was then washed three times PBS before incubation with secondary antibodies 
for 1 h and then incubated 5 minutes with Hoecst. Each coverslip was prepared for 
microscopic examination by applying mounting medium (Prolong Golgi, Invitrogene). 
Images were captured using a Leica DM4000B epifluorescence microscope or a Zeiss 
Axiovert 100M confocal microscope Fluorescent using 60x water-immersion lens. For 
primary antibody see the forward antibody-table. As secondary antibody were used 
Alexa Fluor 468‐conjugated donkey anti-°©‐mouse IgG, Alexa Fluor 488‐ conjugated 
Donkey anti-°©‐rabbit IgG (Invitrogen) for 1 hour at room temperature. 
Antibodies used: 
Target  Antibody  
Lamin V  MAB19562 (Millipore) 
ZO-1 
  
sc-10804 (Santa Cruz)  
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Actin A9718 (Sigma)  
E-cadhrin  #610182 (BD Transduction) 
Vimentin  ab8069 (Abcam) 
 
 
Mammosphere forming efficiency. 
For sphere forming efficiency single cell suspensions derived from monolayer cultures 
were plated at a density of 5000 cells/well into 96-well or 20000cells/well in 24-well 
ultra low attachment plates (Corning) and maintained in MEBM medium (Lonza) 
supplemented with B27 (Invitrogen), 0.2% heparin (Stem Cell Technologies) 5 ug/ml 
insulin (Sigma), 0.5 ug/ml hydrocortisone (Sigma) and 20ng ug /ml EGF (Peprotech) 
and 20 ng /ml bFGF (BD Biosciences). Mammospheres were collected by 
centrifugation upon 10 days and dissociated enzymatically (5 minutes in Trypsin) and 
mechanically by pipetting. Single cells obtained were re-plated for secondary cultures. 
The number of spheres (>50 µm) per well was then counted and expressed as 
percentage ratio of spheres/ plated cells. 
Migration and invasion assays. For migration analysis, transfected cells (1x105) were 
plated on 24 well PET inserts (8.0 µm pore size, Falcon), according to the 
manufacturer’s instructions. For invasion assays cells (1x105) were plated on matrigel-
coated filters (8.0 µm pore size, Falcon) and the lower part of the chamber was filled 
with NIH3T3 conditioned DMEM 10% FBS medium as chemo-attractant. After 16 h or 
24 h respectively, cells on the upper part of the membrane were removed with a cotton 
swab and cells that passed through the filter were fixed in 4% PFA, stained with 0.05% 
crystal violet and counted. 
 
Cells survival curve. 
MDA-MB-231 cells were transfected with indicated siRNA and upon the cell were 
plated in 6 well plated at 1x105 cells/wells. At the indicated times cell growth curve 
was measured by counting the numbers of vitality cells by trypan blue staining and 
replated for the indicated time. 
 
Luciferase Assay. 
For the study of the effect of miR-30d on each 3’UTR reporter, H1299 cells were 
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transfected with 100 ng of each reporter or 100 ng of pGL3-Spacer empty vector, and 
25 ng of CMV-renilla construct were also cotransfected in each point for normalization 
of transfection.. After 24h the cells was splitted and transfected either with 40nM of 
miR-30d or control vector. 6h after transfection, medium was changed and 18h later 
luciferase activity was measured with Dual-Luciferase® Reporter Assay System 
(Promega). Relative Luciferase Units (RLU) were calculated by normalizing the 
luciferase units measured for the firefly (Photinus pyralis) luciferase with the amount of 
Renilla luciferase in each sample. 
Statistical analysis.  
p‑values were obtained by applying a one-tailed, type 2 t‑test ( assuming equal 
variances) using Microsoft Excel. 
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PAPERS NOT DIRECTLY RELEVANT TO THE THESIS 
 
 
During the period of my PhD I have been collaborating in the following publications: 
 
Bisso, A., Faleschini, M., Zampa, F., Capaci, V., De Santa, J., Santarpia, L., Piazza, S., 
et al. (2013). Oncogenic miR-181a/b affect the DNA damage response in aggressive 
breast cancer. Cell Cycle, 12(11), 1679–1687. doi:10.4161/cc.24757 
 
ABSTRACT: Breast cancer is a heterogeneous tumor type characterized by a complex 
spectrum of molecular aberrations, resulting in a diverse array of malignant features and 
clinical outcomes. Deciphering the molecular mechanisms that fuel breast cancer 
development and act as determinants of aggressiveness is a primary need to improve 
patient management. Among other alterations, aberrant expression of microRNAs has 
been found in breast cancer and other human tumors, where they act as either oncogenes 
or tumor suppressors by virtue of their ability to finely modulate gene expression at the 
post-transcriptional level. In this study, we describe a new role for miR-181a/b as 
negative regulators of the DNA damage response in breast cancer, impacting on the 
expression and activity of the stress-sensor kinase ataxia telangiectasia mutated (AtM). 
We report that miR-181a and miR-181b were overexpressed in more aggressive breast 
cancers, and their expression correlates inversely with AtM levels. Moreover we 
demonstrate that deregulated expression of miR-181a/b determines the sensitivity of 
triple-negative breast cancer cells to the poly-ADp-ribose-polymerase1 (pARp1) 
inhibition. these evidences suggest that monitoring the expression of miR-181a/b could 
be helpful in tailoring more effective treatments based on inhibition of pARp1 in breast 
and other tumor types. 
 
Girardini, J. E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, 
V., et al. (2011). A Pin1/Mutant p53 Axis Promotes Aggressiveness in&nbsp;Breast 
Cancer. Cancer Cell, 20(1), 79–91. Elsevier Inc. doi:10.1016/j.ccr.2011.06.004 
 
ABSTRACT: TP53 missense mutations dramatically influence tumor progression, 
however, their mechanism of action is still poorly understood. Here we demonstrate the 
fundamental role of the prolyl isomerase Pin1 in mutant p53 oncogenic functions. Pin1 
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enhances tumorigenesis in a Li-Fraumeni mouse model and cooperates with mutant p53 
in Ras-dependent transformation. In breast cancer cells, Pin1 promotes mutant p53 
depen- dent inhibition of the antimetastatic factor p63 and induction of a mutant p53 
transcriptional program to increase aggressiveness. Furthermore, we identified a 
transcriptional signature associated with poor prog- nosis in breast cancer and, in a 
cohort of patients, Pin1 overexpression influenced the prognostic value of p53 mutation. 
These results define a Pin1/mutant p53 axis that conveys oncogenic signals to promote 
aggres- siveness in human cancers. 
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